WO2009066152A2 - Haloallylamine inhibitors of ssao/vap-1 and uses therefor - Google Patents
Haloallylamine inhibitors of ssao/vap-1 and uses therefor Download PDFInfo
- Publication number
- WO2009066152A2 WO2009066152A2 PCT/IB2008/003124 IB2008003124W WO2009066152A2 WO 2009066152 A2 WO2009066152 A2 WO 2009066152A2 IB 2008003124 W IB2008003124 W IB 2008003124W WO 2009066152 A2 WO2009066152 A2 WO 2009066152A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- amine
- fluorobut
- fluoro
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 28
- 101000774560 Crotalus atrox Zinc metalloproteinase-disintegrin-like VAP1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 219
- 238000000034 method Methods 0.000 claims abstract description 129
- 102100027159 Membrane primary amine oxidase Human genes 0.000 claims abstract description 87
- 101710132836 Membrane primary amine oxidase Proteins 0.000 claims abstract description 80
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 468
- 239000000203 mixture Substances 0.000 claims description 68
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- -1 potency Chemical class 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 37
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 230000004054 inflammatory process Effects 0.000 claims description 31
- QFUSOYKIDBRREL-NSCUHMNNSA-N (e)-but-2-en-1-amine Chemical compound C\C=C\CN QFUSOYKIDBRREL-NSCUHMNNSA-N 0.000 claims description 29
- 102000004316 Oxidoreductases Human genes 0.000 claims description 29
- 108090000854 Oxidoreductases Proteins 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 206010061218 Inflammation Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 23
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 23
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 239000011737 fluorine Substances 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000003368 amide group Chemical group 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 9
- 125000005025 alkynylaryl group Chemical group 0.000 claims description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 claims description 6
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 claims description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 6
- 208000022873 Ocular disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- LVDIGZBRJXVHMH-RMKNXTFCSA-N (e)-3-fluoro-4-(4-methylsulfonylphenoxy)but-2-en-1-amine Chemical compound CS(=O)(=O)C1=CC=C(OC\C(F)=C/CN)C=C1 LVDIGZBRJXVHMH-RMKNXTFCSA-N 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- CMXSEDYRXDTDTC-WEVVVXLNSA-N (e)-3-fluoro-4-(4-fluorophenoxy)but-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(F)C=C1 CMXSEDYRXDTDTC-WEVVVXLNSA-N 0.000 claims description 3
- QSDFWTFBQMZVBH-RMKNXTFCSA-N (e)-3-fluoro-4-phenoxybut-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=CC=C1 QSDFWTFBQMZVBH-RMKNXTFCSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 206010069351 acute lung injury Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- RYHGNBAPPSTONU-VZUCSPMQSA-N (e)-3-fluoro-4-(4-imidazol-1-ylphenoxy)but-2-en-1-amine Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1N1C=NC=C1 RYHGNBAPPSTONU-VZUCSPMQSA-N 0.000 claims description 2
- SZNNZQINCFBHDX-RMKNXTFCSA-N (e)-3-fluoro-4-(4-methoxyphenoxy)but-2-en-1-amine Chemical compound COC1=CC=C(OC\C(F)=C/CN)C=C1 SZNNZQINCFBHDX-RMKNXTFCSA-N 0.000 claims description 2
- JTVDEDCMPNSESX-RMKNXTFCSA-N (e)-3-fluoro-4-(4-methylsulfanylphenoxy)but-2-en-1-amine Chemical compound CSC1=CC=C(OC\C(F)=C/CN)C=C1 JTVDEDCMPNSESX-RMKNXTFCSA-N 0.000 claims description 2
- QSDIKHPIZHACHI-LFYBBSHMSA-N (e)-3-fluoro-4-(4-morpholin-4-ylsulfonylphenoxy)but-2-en-1-amine Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1S(=O)(=O)N1CCOCC1 QSDIKHPIZHACHI-LFYBBSHMSA-N 0.000 claims description 2
- MSNNEDUAEIXZDU-VMPITWQZSA-N (e)-3-fluoro-4-(4-nitrophenoxy)but-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C([N+]([O-])=O)C=C1 MSNNEDUAEIXZDU-VMPITWQZSA-N 0.000 claims description 2
- KRMXWOUKQUUWEU-RUDMXATFSA-N (e)-3-fluoro-4-[(2-methyl-1,3-benzothiazol-5-yl)oxy]but-2-en-1-amine Chemical compound NC\C=C(F)/COC1=CC=C2SC(C)=NC2=C1 KRMXWOUKQUUWEU-RUDMXATFSA-N 0.000 claims description 2
- OWBAPWDINBFKSK-RUDMXATFSA-N (e)-3-fluoro-4-[3-(trifluoromethyl)phenoxy]but-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=CC(C(F)(F)F)=C1 OWBAPWDINBFKSK-RUDMXATFSA-N 0.000 claims description 2
- YJEMLXGENHRZMS-WEVVVXLNSA-N (e)-3-fluoro-4-[4-(trifluoromethyl)phenoxy]but-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(C(F)(F)F)C=C1 YJEMLXGENHRZMS-WEVVVXLNSA-N 0.000 claims description 2
- VQPZYOVPBYUZKH-GORDUTHDSA-N (e)-3-fluoro-4-methoxybut-2-en-1-amine Chemical compound COC\C(F)=C/CN VQPZYOVPBYUZKH-GORDUTHDSA-N 0.000 claims description 2
- WASPRTQJQMWTAE-XVNBXDOJSA-N (e)-4-(3,4-difluorophenoxy)-3-fluorobut-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(F)C(F)=C1 WASPRTQJQMWTAE-XVNBXDOJSA-N 0.000 claims description 2
- FCYOQNRECMAIAJ-XYOKQWHBSA-N (e)-4-(4-tert-butylphenoxy)-3-fluorobut-2-en-1-amine Chemical compound CC(C)(C)C1=CC=C(OC\C(F)=C/CN)C=C1 FCYOQNRECMAIAJ-XYOKQWHBSA-N 0.000 claims description 2
- ZMDUCNSCHDPZPM-CLTKARDFSA-N (z)-3-chloro-4-(2-chloro-4-nitrophenoxy)but-2-en-1-amine Chemical compound NC\C=C(/Cl)COC1=CC=C([N+]([O-])=O)C=C1Cl ZMDUCNSCHDPZPM-CLTKARDFSA-N 0.000 claims description 2
- YJEMLXGENHRZMS-UITAMQMPSA-N (z)-3-fluoro-4-[4-(trifluoromethyl)phenoxy]but-2-en-1-amine Chemical compound NC\C=C(/F)COC1=CC=C(C(F)(F)F)C=C1 YJEMLXGENHRZMS-UITAMQMPSA-N 0.000 claims description 2
- QSDFWTFBQMZVBH-TWGQIWQCSA-N (z)-3-fluoro-4-phenoxybut-2-en-1-amine Chemical compound NC\C=C(/F)COC1=CC=CC=C1 QSDFWTFBQMZVBH-TWGQIWQCSA-N 0.000 claims description 2
- IYKWLUKSVIWFBS-BAQGIRSFSA-N (z)-4-(2,4-dichlorophenoxy)-3-fluorobut-2-en-1-amine Chemical compound NC\C=C(/F)COC1=CC=C(Cl)C=C1Cl IYKWLUKSVIWFBS-BAQGIRSFSA-N 0.000 claims description 2
- ZHEASPQKHRFKHU-MHWRWJLKSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-benzylbenzamide Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1C(=O)NCC1=CC=CC=C1 ZHEASPQKHRFKHU-MHWRWJLKSA-N 0.000 claims description 2
- XVWFLTZRHVOLDH-UVTDQMKNSA-N 4-[(z)-4-amino-2-fluorobut-2-enoxy]-n-cyclohexylbenzamide Chemical compound C1=CC(OCC(/F)=C/CN)=CC=C1C(=O)NC1CCCCC1 XVWFLTZRHVOLDH-UVTDQMKNSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 2
- 230000004797 therapeutic response Effects 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- ZMDUCNSCHDPZPM-XVNBXDOJSA-N (e)-3-chloro-4-(2-chloro-4-nitrophenoxy)but-2-en-1-amine Chemical compound NC\C=C(\Cl)COC1=CC=C([N+]([O-])=O)C=C1Cl ZMDUCNSCHDPZPM-XVNBXDOJSA-N 0.000 claims 1
- QWAKWHPIXHHAHU-LFIBNONCSA-N (e)-3-fluoro-4-[4-(1-phenylethylsulfonyl)phenoxy]but-2-en-1-amine Chemical compound C=1C=C(OC\C(F)=C/CN)C=CC=1S(=O)(=O)C(C)C1=CC=CC=C1 QWAKWHPIXHHAHU-LFIBNONCSA-N 0.000 claims 1
- WEOPUEZOYZVLEZ-MHWRWJLKSA-N (e)-3-fluoro-4-[4-(2-phenylethylsulfonyl)phenoxy]but-2-en-1-amine Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1S(=O)(=O)CCC1=CC=CC=C1 WEOPUEZOYZVLEZ-MHWRWJLKSA-N 0.000 claims 1
- KIYUARNJTMZZAU-VMPITWQZSA-N (e)-3-fluoro-4-[4-(trifluoromethylsulfonyl)phenoxy]but-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 KIYUARNJTMZZAU-VMPITWQZSA-N 0.000 claims 1
- DTYBMEJCSKRUHI-RIYZIHGNSA-N (e)-3-fluoro-4-[[2-(4-methylphenyl)-1,3-benzothiazol-5-yl]oxy]but-2-en-1-amine Chemical compound C1=CC(C)=CC=C1C1=NC2=CC(OC\C(F)=C/CN)=CC=C2S1 DTYBMEJCSKRUHI-RIYZIHGNSA-N 0.000 claims 1
- PPABKTSTGGPHFA-RIYZIHGNSA-N (e)-3-fluoro-4-[[2-(4-methylphenyl)-1,3-benzothiazol-6-yl]oxy]but-2-en-1-amine Chemical compound C1=CC(C)=CC=C1C1=NC2=CC=C(OC\C(F)=C/CN)C=C2S1 PPABKTSTGGPHFA-RIYZIHGNSA-N 0.000 claims 1
- VYGKPOOALNDJLF-XVNBXDOJSA-N (e)-4-(3-chloro-4-fluorophenoxy)-3-fluorobut-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(F)C(Cl)=C1 VYGKPOOALNDJLF-XVNBXDOJSA-N 0.000 claims 1
- RQXKISCKJWNDGS-MDWZMJQESA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-3-chloro-n-cyclohexylbenzamide Chemical compound C1=C(Cl)C(OCC(\F)=C/CN)=CC=C1C(=O)NC1CCCCC1 RQXKISCKJWNDGS-MDWZMJQESA-N 0.000 claims 1
- UBDCECRNDLSLAO-PJQLUOCWSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1C(=O)NCC1=CC(F)=CC(C(F)(F)F)=C1 UBDCECRNDLSLAO-PJQLUOCWSA-N 0.000 claims 1
- XVRAAVWZCUJQCN-MDWZMJQESA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-cyclohexyl-3-fluorobenzamide Chemical compound C1=C(F)C(OCC(\F)=C/CN)=CC=C1C(=O)NC1CCCCC1 XVRAAVWZCUJQCN-MDWZMJQESA-N 0.000 claims 1
- FCLNCLFIIJHHCU-LGMDPLHJSA-N 4-[(z)-4-amino-2-fluoro-3-methylbut-2-enoxy]-n-cyclohexylbenzamide Chemical compound C1=CC(OCC(\F)=C(CN)/C)=CC=C1C(=O)NC1CCCCC1 FCLNCLFIIJHHCU-LGMDPLHJSA-N 0.000 claims 1
- MFEZONASAAYZDZ-UHFFFAOYSA-N FC(C=CCOC1=CC=C(C=C1)S(=O)(=O)CCN1CCCC1)N Chemical compound FC(C=CCOC1=CC=C(C=C1)S(=O)(=O)CCN1CCCC1)N MFEZONASAAYZDZ-UHFFFAOYSA-N 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 28
- 208000027866 inflammatory disease Diseases 0.000 abstract description 13
- 229910052740 iodine Inorganic materials 0.000 abstract description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 140
- 238000005160 1H NMR spectroscopy Methods 0.000 description 119
- 239000000047 product Substances 0.000 description 110
- 239000007787 solid Substances 0.000 description 60
- 239000000843 powder Substances 0.000 description 57
- 239000000243 solution Substances 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- DVEMVHCJYUKOPX-QPJJXVBHSA-N tert-butyl n-[(e)-3-fluoro-4-hydroxybut-2-enyl]carbamate Chemical compound CC(C)(C)OC(=O)NC\C=C(\F)CO DVEMVHCJYUKOPX-QPJJXVBHSA-N 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- 239000002904 solvent Substances 0.000 description 34
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- 102000010909 Monoamine Oxidase Human genes 0.000 description 27
- 108010062431 Monoamine oxidase Proteins 0.000 description 27
- 239000003153 chemical reaction reagent Substances 0.000 description 23
- CVDGIEIMXIVMAS-QPJJXVBHSA-N tert-butyl n-[(e)-4-bromo-3-fluorobut-2-enyl]carbamate Chemical compound CC(C)(C)OC(=O)NC\C=C(\F)CBr CVDGIEIMXIVMAS-QPJJXVBHSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- 125000004429 atom Chemical group 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- XZWMBNYVEVBRQD-UHFFFAOYSA-N (3-fluoro-4-hydroxybut-2-enyl)carbamic acid Chemical compound OCC(F)=CCNC(O)=O XZWMBNYVEVBRQD-UHFFFAOYSA-N 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 101000694615 Homo sapiens Membrane primary amine oxidase Proteins 0.000 description 11
- HNVAXILPAPSDDS-SQQVDAMQSA-N [(e)-but-2-enyl]azanium;chloride Chemical compound Cl.C\C=C\CN HNVAXILPAPSDDS-SQQVDAMQSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 9
- VXLBSYHAEKDUSU-JXMROGBWSA-N (2e)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine Chemical compound NC\C(=C\F)CCC1=CC=C(F)C=C1 VXLBSYHAEKDUSU-JXMROGBWSA-N 0.000 description 8
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- HAQXDKLHUARIMI-UHFFFAOYSA-N (4-bromo-3-fluorobut-2-enyl)carbamic acid Chemical compound OC(=O)NCC=C(F)CBr HAQXDKLHUARIMI-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000008176 lyophilized powder Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 229950010854 mofegiline Drugs 0.000 description 7
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 150000002989 phenols Chemical class 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 5
- 239000005977 Ethylene Substances 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 239000006215 rectal suppository Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 0 *C(*)=C(*)CN* Chemical compound *C(*)=C(*)CN* 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001241 acetals Chemical class 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 4
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 4
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 4
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 208000024714 major depressive disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- YEVXGCOKTNQCHD-UHFFFAOYSA-N n-cyclohexyl-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NC1CCCCC1 YEVXGCOKTNQCHD-UHFFFAOYSA-N 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 4
- ZJFTZQUVVDDAGU-TWGQIWQCSA-N (e)-3-chloro-2-phenylprop-2-en-1-amine Chemical compound NC\C(=C\Cl)C1=CC=CC=C1 ZJFTZQUVVDDAGU-TWGQIWQCSA-N 0.000 description 3
- BOFRXDMCQRTGII-UHFFFAOYSA-N 619-08-9 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1Cl BOFRXDMCQRTGII-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 208000028683 bipolar I disease Diseases 0.000 description 3
- 208000025307 bipolar depression Diseases 0.000 description 3
- 201000009267 bronchiectasis Diseases 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229960003946 selegiline Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- GLCWNRBQLBWFAD-FMIVXFBMSA-N tert-butyl n-[(e)-3-fluoro-4-phenoxybut-2-enyl]carbamate Chemical compound CC(C)(C)OC(=O)NC\C=C(\F)COC1=CC=CC=C1 GLCWNRBQLBWFAD-FMIVXFBMSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229940117958 vinyl acetate Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GLDHNLLONWGZQT-UHFFFAOYSA-N (3-chloro-4-hydroxybut-2-enyl)carbamic acid Chemical compound OCC(Cl)=CCNC(O)=O GLDHNLLONWGZQT-UHFFFAOYSA-N 0.000 description 2
- DBTVSXPEFDJKQX-MHWRWJLKSA-N (e)-3-fluoro-4-[4-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]phenoxy]but-2-en-1-amine Chemical compound C1=CC(OC)=CC=C1C1=CSC(C=2C=CC(OC\C(F)=C/CN)=CC=2)=N1 DBTVSXPEFDJKQX-MHWRWJLKSA-N 0.000 description 2
- JYOXYHHSKLBBIJ-MLBSPLJJSA-N (e)-3-fluoro-4-phenoxybut-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=CC=C1 JYOXYHHSKLBBIJ-MLBSPLJJSA-N 0.000 description 2
- ITCFVEUDZNZXGP-XBXARRHUSA-N (e)-4-(2-chloro-4-methylsulfonylphenoxy)-3-fluorobut-2-en-1-amine Chemical compound CS(=O)(=O)C1=CC=C(OC\C(F)=C/CN)C(Cl)=C1 ITCFVEUDZNZXGP-XBXARRHUSA-N 0.000 description 2
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 2
- WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 2
- IFFDDFKAXIGKOR-BJMVGYQFSA-N 2-[4-[(e)-4-amino-2-fluorobut-2-enoxy]phenyl]sulfonylethanol Chemical compound NC\C=C(\F)COC1=CC=C(S(=O)(=O)CCO)C=C1 IFFDDFKAXIGKOR-BJMVGYQFSA-N 0.000 description 2
- AQSRRZGQRFFFGS-UHFFFAOYSA-N 2-methylpyridin-3-ol Chemical compound CC1=NC=CC=C1O AQSRRZGQRFFFGS-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- BAYGVMXZJBFEMB-UHFFFAOYSA-N 4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 2
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 2
- KECCFSZFXLAGJS-UHFFFAOYSA-N 4-methylsulfonylphenol Chemical compound CS(=O)(=O)C1=CC=C(O)C=C1 KECCFSZFXLAGJS-UHFFFAOYSA-N 0.000 description 2
- ZSBDGXGICLIJGD-UHFFFAOYSA-N 4-phenoxyphenol Chemical compound C1=CC(O)=CC=C1OC1=CC=CC=C1 ZSBDGXGICLIJGD-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- DHLUJPLHLZJUBW-UHFFFAOYSA-N 6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C=N1 DHLUJPLHLZJUBW-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- NSNPYIPDZOUXRV-KPKJPENVSA-N CC(C)NC(c(cc1)ccc1OC/C(/F)=C\CN)=O Chemical compound CC(C)NC(c(cc1)ccc1OC/C(/F)=C\CN)=O NSNPYIPDZOUXRV-KPKJPENVSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008355 dextrose injection Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 150000002084 enol ethers Chemical class 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 108010070912 mouse semicarbazide-sensitive amine oxidase-vascular adhesion protein-1 Proteins 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- DVEMVHCJYUKOPX-UHFFFAOYSA-N tert-butyl n-(3-fluoro-4-hydroxybut-2-enyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=C(F)CO DVEMVHCJYUKOPX-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- TVSZANUGCWVMEH-UHFFFAOYSA-N (3-fluoro-4-hydroxybut-2-enyl) carbamate Chemical compound NC(=O)OCC=C(F)CO TVSZANUGCWVMEH-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZKLMYAVIKBNKPN-UHFFFAOYSA-N (4-hydroxyphenyl)-pyrrolidin-1-ylmethanone Chemical compound C1=CC(O)=CC=C1C(=O)N1CCCC1 ZKLMYAVIKBNKPN-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GDJXIJGAJQKJNK-HPJBNNNXSA-N (e)-3-fluoro-4-(2-methylpyridin-3-yl)oxybut-2-en-1-amine;dihydrochloride Chemical compound Cl.Cl.CC1=NC=CC=C1OC\C(F)=C/CN GDJXIJGAJQKJNK-HPJBNNNXSA-N 0.000 description 1
- FBELHPIJPJFDQK-SZKNIZGXSA-N (e)-3-fluoro-4-(4-fluorophenoxy)but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=C(F)C=C1 FBELHPIJPJFDQK-SZKNIZGXSA-N 0.000 description 1
- XSAWXDHAFGYDPA-MLBSPLJJSA-N (e)-3-fluoro-4-(4-methoxyphenoxy)but-2-en-1-amine;hydrochloride Chemical compound Cl.COC1=CC=C(OC\C(F)=C/CN)C=C1 XSAWXDHAFGYDPA-MLBSPLJJSA-N 0.000 description 1
- DSSOUEFCDUKJIA-RMKNXTFCSA-N (e)-3-fluoro-4-(4-methylsulfinylphenoxy)but-2-en-1-amine Chemical compound CS(=O)C1=CC=C(OC\C(F)=C/CN)C=C1 DSSOUEFCDUKJIA-RMKNXTFCSA-N 0.000 description 1
- SGDICEIJTHDLQY-MLBSPLJJSA-N (e)-3-fluoro-4-(4-methylsulfonylphenoxy)but-2-en-1-amine;hydrochloride Chemical compound Cl.CS(=O)(=O)C1=CC=C(OC\C(F)=C/CN)C=C1 SGDICEIJTHDLQY-MLBSPLJJSA-N 0.000 description 1
- AFNYWSWEWHVIJD-NKPNRJPBSA-N (e)-3-fluoro-4-(4-morpholin-4-ylsulfonylphenoxy)but-2-en-1-amine;hydrochloride Chemical compound Cl.C1=CC(OCC(\F)=C/CN)=CC=C1S(=O)(=O)N1CCOCC1 AFNYWSWEWHVIJD-NKPNRJPBSA-N 0.000 description 1
- GSJKBESRKSXHOS-YRNVUSSQSA-N (e)-3-fluoro-4-(4-propan-2-ylsulfonylphenoxy)but-2-en-1-amine Chemical compound CC(C)S(=O)(=O)C1=CC=C(OC\C(F)=C/CN)C=C1 GSJKBESRKSXHOS-YRNVUSSQSA-N 0.000 description 1
- MVFJWLVQFBMJSH-HPJBNNNXSA-N (e)-3-fluoro-4-(6-methylpyridin-3-yl)oxybut-2-en-1-amine;dihydrochloride Chemical compound Cl.Cl.CC1=CC=C(OC\C(F)=C/CN)C=N1 MVFJWLVQFBMJSH-HPJBNNNXSA-N 0.000 description 1
- GSZBMRMKZKBWAP-JOKMOOFLSA-N (e)-3-fluoro-4-[3-(trifluoromethyl)phenoxy]but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=CC(C(F)(F)F)=C1 GSZBMRMKZKBWAP-JOKMOOFLSA-N 0.000 description 1
- RUNPGIQBOKNPCW-YFMOEUEHSA-N (e)-3-fluoro-4-[4-(1-phenylethylsulfonyl)phenoxy]but-2-en-1-amine;hydrochloride Chemical compound Cl.C=1C=C(OC\C(F)=C/CN)C=CC=1S(=O)(=O)C(C)C1=CC=CC=C1 RUNPGIQBOKNPCW-YFMOEUEHSA-N 0.000 description 1
- RBKZYJYLJKAJCJ-VGOFMYFVSA-N (e)-3-fluoro-4-[4-(2-pyrrolidin-1-ylethylsulfonyl)phenoxy]but-2-en-1-amine Chemical compound C1=CC(OCC(\F)=C/CN)=CC=C1S(=O)(=O)CCN1CCCC1 RBKZYJYLJKAJCJ-VGOFMYFVSA-N 0.000 description 1
- HDYRRIKTUADJDR-HAAWTFQLSA-N (e)-3-fluoro-4-[4-(trifluoromethoxy)phenoxy]but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=C(OC(F)(F)F)C=C1 HDYRRIKTUADJDR-HAAWTFQLSA-N 0.000 description 1
- LESRQFJEXVUESN-SZKNIZGXSA-N (e)-3-fluoro-4-[4-(trifluoromethyl)phenoxy]but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=C(C(F)(F)F)C=C1 LESRQFJEXVUESN-SZKNIZGXSA-N 0.000 description 1
- GUZZGHRANBYWHN-NTUHNPAUSA-N (e)-3-fluoro-4-naphthalen-2-yloxybut-2-en-1-amine Chemical compound C1=CC=CC2=CC(OCC(\F)=C/CN)=CC=C21 GUZZGHRANBYWHN-NTUHNPAUSA-N 0.000 description 1
- UAKVCPAICMTPFN-HAAWTFQLSA-N (e)-4-(1,3-benzothiazol-2-yloxy)-3-fluorobut-2-en-1-amine;hydrochloride Chemical compound Cl.C1=CC=C2SC(OCC(\F)=C/CN)=NC2=C1 UAKVCPAICMTPFN-HAAWTFQLSA-N 0.000 description 1
- IYKWLUKSVIWFBS-FPYGCLRLSA-N (e)-4-(2,4-dichlorophenoxy)-3-fluorobut-2-en-1-amine Chemical compound NC\C=C(\F)COC1=CC=C(Cl)C=C1Cl IYKWLUKSVIWFBS-FPYGCLRLSA-N 0.000 description 1
- DGTLEUICDLWDPR-DCDCITSCSA-N (e)-4-(2,4-dichlorophenoxy)-3-fluorobut-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=C(Cl)C=C1Cl DGTLEUICDLWDPR-DCDCITSCSA-N 0.000 description 1
- GERDTQRDNZSYFY-CDQVLDCRSA-N (e)-4-(3,4-difluorophenoxy)-3-fluorobut-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(\F)COC1=CC=C(F)C(F)=C1 GERDTQRDNZSYFY-CDQVLDCRSA-N 0.000 description 1
- GOPRGGWOBDADRI-MXZHIVQLSA-N (e)-4-(4-tert-butylphenoxy)-3-fluorobut-2-en-1-amine;hydrochloride Chemical compound Cl.CC(C)(C)C1=CC=C(OC\C(F)=C/CN)C=C1 GOPRGGWOBDADRI-MXZHIVQLSA-N 0.000 description 1
- AIXJPHVSBYAARJ-UXBLZVDNSA-N (e)-4-[(2-tert-butyl-1,3-benzothiazol-5-yl)oxy]-3-fluorobut-2-en-1-amine Chemical compound NC\C=C(F)/COC1=CC=C2SC(C(C)(C)C)=NC2=C1 AIXJPHVSBYAARJ-UXBLZVDNSA-N 0.000 description 1
- LKJJCHLABOLAEH-WYLUAFJRSA-N (z)-3-chloro-4-(2-chloro-4-nitrophenoxy)but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(/Cl)COC1=CC=C([N+]([O-])=O)C=C1Cl LKJJCHLABOLAEH-WYLUAFJRSA-N 0.000 description 1
- LESRQFJEXVUESN-UYTGOYFPSA-N (z)-3-fluoro-4-[4-(trifluoromethyl)phenoxy]but-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(/F)COC1=CC=C(C(F)(F)F)C=C1 LESRQFJEXVUESN-UYTGOYFPSA-N 0.000 description 1
- JYOXYHHSKLBBIJ-BORNJIKYSA-N (z)-3-fluoro-4-phenoxybut-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(/F)COC1=CC=CC=C1 JYOXYHHSKLBBIJ-BORNJIKYSA-N 0.000 description 1
- DGTLEUICDLWDPR-NGRDVXTNSA-N (z)-4-(2,4-dichlorophenoxy)-3-fluorobut-2-en-1-amine;hydrochloride Chemical compound Cl.NC\C=C(/F)COC1=CC=C(Cl)C=C1Cl DGTLEUICDLWDPR-NGRDVXTNSA-N 0.000 description 1
- XWAOSJLMXCZMHD-IWQZZHSRSA-N (z)-4-amino-2-fluorobut-2-enoic acid Chemical compound NC\C=C(/F)C(O)=O XWAOSJLMXCZMHD-IWQZZHSRSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- AGRIQBHIKABLPJ-UHFFFAOYSA-N 1-Pyrrolidinecarboxaldehyde Chemical compound O=CN1CCCC1 AGRIQBHIKABLPJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- BTGAEQQHTVMDOB-UHFFFAOYSA-N 2-(4-methylphenyl)-1,3-benzothiazol-5-ol Chemical compound C1=CC(C)=CC=C1C1=NC2=CC(O)=CC=C2S1 BTGAEQQHTVMDOB-UHFFFAOYSA-N 0.000 description 1
- BDYBDKIBLZTCDW-UHFFFAOYSA-N 2-(4-methylphenyl)-1,3-benzothiazol-6-ol Chemical compound C1=CC(C)=CC=C1C1=NC2=CC=C(O)C=C2S1 BDYBDKIBLZTCDW-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- NKCJTSDDCIJRLT-UHFFFAOYSA-N 2-chloro-4-methylsulfonylphenol Chemical compound CS(=O)(=O)C1=CC=C(O)C(Cl)=C1 NKCJTSDDCIJRLT-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- HNNFTKKQOKHHOP-UHFFFAOYSA-N 2-cyclohexyl-1,3-benzothiazol-5-ol Chemical compound N=1C2=CC(O)=CC=C2SC=1C1CCCCC1 HNNFTKKQOKHHOP-UHFFFAOYSA-N 0.000 description 1
- SQRJSQXBBOCEKK-UHFFFAOYSA-N 2-fluoro-4-[(2-methylpropan-2-yl)oxycarbonylamino]but-2-enoic acid Chemical compound CC(C)(C)OC(=O)NCC=C(C(=O)O)F SQRJSQXBBOCEKK-UHFFFAOYSA-N 0.000 description 1
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LAKVUPMDDFICNR-UHFFFAOYSA-N 2-methyl-1,3-benzothiazol-5-ol Chemical compound OC1=CC=C2SC(C)=NC2=C1 LAKVUPMDDFICNR-UHFFFAOYSA-N 0.000 description 1
- ROFBPPIQUBJMRO-UHFFFAOYSA-N 2-methyl-1,3-benzothiazol-6-ol Chemical compound C1=C(O)C=C2SC(C)=NC2=C1 ROFBPPIQUBJMRO-UHFFFAOYSA-N 0.000 description 1
- USDVTWIZDAEZQT-UHFFFAOYSA-N 2-oxopropylcarbamic acid Chemical compound CC(=O)CNC(O)=O USDVTWIZDAEZQT-UHFFFAOYSA-N 0.000 description 1
- BCTTWPKVSZMCGB-UHFFFAOYSA-N 2-tert-butyl-1,3-benzothiazol-5-ol Chemical compound OC1=CC=C2SC(C(C)(C)C)=NC2=C1 BCTTWPKVSZMCGB-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- BNPWVUJOPCGHIK-UHFFFAOYSA-N 3,4-difluorophenol Chemical compound OC1=CC=C(F)C(F)=C1 BNPWVUJOPCGHIK-UHFFFAOYSA-N 0.000 description 1
- NCLQISLGSIYQAH-UHFFFAOYSA-N 3,5-dichloro-n-cyclohexyl-4-hydroxybenzamide Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)NC1CCCCC1 NCLQISLGSIYQAH-UHFFFAOYSA-N 0.000 description 1
- VPOMSPZBQMDLTM-UHFFFAOYSA-N 3,5-dichlorophenol Chemical compound OC1=CC(Cl)=CC(Cl)=C1 VPOMSPZBQMDLTM-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- ZQXLIXHVJVAPLW-UHFFFAOYSA-N 3-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C(Cl)=C1 ZQXLIXHVJVAPLW-UHFFFAOYSA-N 0.000 description 1
- HOGCGGJZAPIVJD-UHFFFAOYSA-N 3-chloro-n-cyclohexyl-4-hydroxybenzamide Chemical compound C1=C(Cl)C(O)=CC=C1C(=O)NC1CCCCC1 HOGCGGJZAPIVJD-UHFFFAOYSA-N 0.000 description 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 description 1
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical class C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
- RXRYQGSBCFQVNP-UHFFFAOYSA-N 3-methyl-4-(2-methyl-1,3-thiazol-4-yl)phenol Chemical compound S1C(C)=NC(C=2C(=CC(O)=CC=2)C)=C1 RXRYQGSBCFQVNP-UHFFFAOYSA-N 0.000 description 1
- KGPGKOSHODHUSR-UHFFFAOYSA-N 3-methyl-4-methylsulfonylphenol Chemical compound CC1=CC(O)=CC=C1S(C)(=O)=O KGPGKOSHODHUSR-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- 150000004066 3-pyrrolines Chemical class 0.000 description 1
- IRBPGESFKVHEHW-UHFFFAOYSA-N 4-(1-phenylethylsulfonyl)phenol Chemical compound C=1C=C(O)C=CC=1S(=O)(=O)C(C)C1=CC=CC=C1 IRBPGESFKVHEHW-UHFFFAOYSA-N 0.000 description 1
- CYKCUAPYWQDIKR-UHFFFAOYSA-N 4-(1h-imidazol-1-yl)phenol Chemical compound C1=CC(O)=CC=C1N1C=NC=C1 CYKCUAPYWQDIKR-UHFFFAOYSA-N 0.000 description 1
- XKAYIGNWXGSZIN-UHFFFAOYSA-N 4-(2,2-dimethylpropylsulfonyl)phenol Chemical compound CC(C)(C)CS(=O)(=O)C1=CC=C(O)C=C1 XKAYIGNWXGSZIN-UHFFFAOYSA-N 0.000 description 1
- BOIHODSRENFRLH-UHFFFAOYSA-N 4-(2-hydroxyethylsulfonyl)phenol Chemical compound OCCS(=O)(=O)C1=CC=C(O)C=C1 BOIHODSRENFRLH-UHFFFAOYSA-N 0.000 description 1
- LRSOIINFIJUUMK-UHFFFAOYSA-N 4-(2-methylpropylsulfonyl)phenol Chemical compound CC(C)CS(=O)(=O)C1=CC=C(O)C=C1 LRSOIINFIJUUMK-UHFFFAOYSA-N 0.000 description 1
- SDEROGAHQNZBCX-UHFFFAOYSA-N 4-(2-morpholin-4-ylethylsulfonyl)phenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CCN1CCOCC1 SDEROGAHQNZBCX-UHFFFAOYSA-N 0.000 description 1
- YHPUCLNGVLILLB-UHFFFAOYSA-N 4-(2-phenylethylsulfonyl)phenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CCC1=CC=CC=C1 YHPUCLNGVLILLB-UHFFFAOYSA-N 0.000 description 1
- XZSSDPRTLIKCFI-UHFFFAOYSA-N 4-(2-piperidin-1-ylethylsulfonyl)phenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CCN1CCCCC1 XZSSDPRTLIKCFI-UHFFFAOYSA-N 0.000 description 1
- VEDUENLHGITKEA-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylethylsulfonyl)phenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CCN1CCCC1 VEDUENLHGITKEA-UHFFFAOYSA-N 0.000 description 1
- ZHEBOGJEFDFDSQ-UHFFFAOYSA-N 4-(4,4-dimethyl-5H-1,3-oxazol-2-yl)phenol Chemical compound CC1(C)COC(C=2C=CC(O)=CC=2)=N1 ZHEBOGJEFDFDSQ-UHFFFAOYSA-N 0.000 description 1
- QASBCTGZKABPKX-UHFFFAOYSA-N 4-(methylsulfanyl)phenol Chemical compound CSC1=CC=C(O)C=C1 QASBCTGZKABPKX-UHFFFAOYSA-N 0.000 description 1
- WDRJNKMAZMEYOF-UHFFFAOYSA-N 4-(trifluoromethoxy)phenol Chemical compound OC1=CC=C(OC(F)(F)F)C=C1 WDRJNKMAZMEYOF-UHFFFAOYSA-N 0.000 description 1
- NPFYZDNDJHZQKY-UHFFFAOYSA-N 4-Hydroxybenzophenone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 NPFYZDNDJHZQKY-UHFFFAOYSA-N 0.000 description 1
- GGGLSWPTGJFUIL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methylsulfonyl]phenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CC1=CC=C(F)C=C1 GGGLSWPTGJFUIL-UHFFFAOYSA-N 0.000 description 1
- SXJPBBLUTYIIBF-WXIWBVQFSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-3,5-dichloro-n-cyclohexylbenzamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(OCC(\F)=C/CN)=C(Cl)C=C1C(=O)NC1CCCCC1 SXJPBBLUTYIIBF-WXIWBVQFSA-N 0.000 description 1
- BUBGWEXVCLHAMT-NBYYMMLRSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n,n-diethylbenzenesulfonamide;hydrochloride Chemical compound Cl.CCN(CC)S(=O)(=O)C1=CC=C(OC\C(F)=C/CN)C=C1 BUBGWEXVCLHAMT-NBYYMMLRSA-N 0.000 description 1
- NNUPNCVHTOOKRU-SJDTYFKWSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-benzyl-n-methylbenzamide;hydrochloride Chemical compound Cl.C=1C=C(OC\C(F)=C/CN)C=CC=1C(=O)N(C)CC1=CC=CC=C1 NNUPNCVHTOOKRU-SJDTYFKWSA-N 0.000 description 1
- AUPREWZBLCSWFD-QFHYWFJHSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-benzylbenzamide;hydrochloride Chemical compound Cl.C1=CC(OCC(\F)=C/CN)=CC=C1C(=O)NCC1=CC=CC=C1 AUPREWZBLCSWFD-QFHYWFJHSA-N 0.000 description 1
- UWOCUNHKIIBLSB-KJEVSKRMSA-N 4-[(e)-4-amino-2-fluorobut-2-enoxy]-n-cyclopentylbenzamide;hydrochloride Chemical compound Cl.C1=CC(OCC(\F)=C/CN)=CC=C1C(=O)NC1CCCC1 UWOCUNHKIIBLSB-KJEVSKRMSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- SBPARSMFCCDDFH-UHFFFAOYSA-N 4-benzylsulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)CC1=CC=CC=C1 SBPARSMFCCDDFH-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- ILZKHWRDXQITIH-UHFFFAOYSA-N 4-butan-2-ylsulfonylphenol Chemical compound CCC(C)S(=O)(=O)C1=CC=C(O)C=C1 ILZKHWRDXQITIH-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- CGOGVKJTSPTREP-UHFFFAOYSA-N 4-cyclopentylsulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1CCCC1 CGOGVKJTSPTREP-UHFFFAOYSA-N 0.000 description 1
- QIFHJXTUYMXRID-UHFFFAOYSA-N 4-ethylsulfonylphenol Chemical compound CCS(=O)(=O)C1=CC=C(O)C=C1 QIFHJXTUYMXRID-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- ALEVUYMOJKJJSA-UHFFFAOYSA-N 4-hydroxy-2-propylbenzoic acid Chemical class CCCC1=CC(O)=CC=C1C(O)=O ALEVUYMOJKJJSA-UHFFFAOYSA-N 0.000 description 1
- JYBMFOQKJJJCPY-UHFFFAOYSA-N 4-hydroxy-N,N-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(O)C=C1 JYBMFOQKJJJCPY-UHFFFAOYSA-N 0.000 description 1
- YIJWBPAOJXIYJY-UHFFFAOYSA-N 4-hydroxy-n,n-di(propan-2-yl)benzamide Chemical compound CC(C)N(C(C)C)C(=O)C1=CC=C(O)C=C1 YIJWBPAOJXIYJY-UHFFFAOYSA-N 0.000 description 1
- UJCPSWBVHQROQF-UHFFFAOYSA-N 4-hydroxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(O)C=C1 UJCPSWBVHQROQF-UHFFFAOYSA-N 0.000 description 1
- KRQNPHSRSFGURC-UHFFFAOYSA-N 4-hydroxy-n-(1-phenylethyl)benzenesulfonamide Chemical compound C=1C=CC=CC=1C(C)NS(=O)(=O)C1=CC=C(O)C=C1 KRQNPHSRSFGURC-UHFFFAOYSA-N 0.000 description 1
- RMHMYTLAUXIOPR-UHFFFAOYSA-N 4-hydroxy-n-phenylbenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NC1=CC=CC=C1 RMHMYTLAUXIOPR-UHFFFAOYSA-N 0.000 description 1
- GOCVDDAVCVFQMM-UHFFFAOYSA-N 4-hydroxy-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=C(O)C=C1 GOCVDDAVCVFQMM-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- LYIHIMLRHVZNJK-UHFFFAOYSA-N 4-morpholin-4-ylsulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)N1CCOCC1 LYIHIMLRHVZNJK-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QEYQMWSESURNPP-UHFFFAOYSA-N 4-propan-2-yloxyphenol Chemical compound CC(C)OC1=CC=C(O)C=C1 QEYQMWSESURNPP-UHFFFAOYSA-N 0.000 description 1
- YPEFHWAPVJSBBU-UHFFFAOYSA-N 4-propan-2-ylsulfonylphenol Chemical compound CC(C)S(=O)(=O)C1=CC=C(O)C=C1 YPEFHWAPVJSBBU-UHFFFAOYSA-N 0.000 description 1
- MISYZISDEPUMMN-UHFFFAOYSA-N 4-pyrrolidin-1-ylsulfonylphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)N1CCCC1 MISYZISDEPUMMN-UHFFFAOYSA-N 0.000 description 1
- PRLINSMUYJWPBL-UHFFFAOYSA-N 4-tert-butyl-2-chlorophenol Chemical compound CC(C)(C)C1=CC=C(O)C(Cl)=C1 PRLINSMUYJWPBL-UHFFFAOYSA-N 0.000 description 1
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- GWPGDZPXOZATKL-UHFFFAOYSA-N 9h-carbazol-2-ol Chemical compound C1=CC=C2C3=CC=C(O)C=C3NC2=C1 GWPGDZPXOZATKL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010079340 Benzylamine Oxidase Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- FCLNCLFIIJHHCU-GHRIWEEISA-N C/C(/CN)=C(/COc(cc1)ccc1C(NC1CCCCC1)=O)\F Chemical compound C/C(/CN)=C(/COc(cc1)ccc1C(NC1CCCCC1)=O)\F FCLNCLFIIJHHCU-GHRIWEEISA-N 0.000 description 1
- JZRUPKCLCRBYRZ-SILNSSARSA-N CC(C)(C)OC(NC/C(/C)=C(/COc(cc1)ccc1C(NC1CCCCC1)=O)\F)=O Chemical compound CC(C)(C)OC(NC/C(/C)=C(/COc(cc1)ccc1C(NC1CCCCC1)=O)\F)=O JZRUPKCLCRBYRZ-SILNSSARSA-N 0.000 description 1
- AJHIFEMXBVIBRH-LFIBNONCSA-N CC(c1ccccc1)NS(C(C=C1)=CCC1OC/C(/F)=C\CN)(=O)=O Chemical compound CC(c1ccccc1)NS(C(C=C1)=CCC1OC/C(/F)=C\CN)(=O)=O AJHIFEMXBVIBRH-LFIBNONCSA-N 0.000 description 1
- LPXWSQAEVYFMLL-UHFFFAOYSA-N C[SH-](c(cc1)ccc1OCC(F)=CCN)=C Chemical compound C[SH-](c(cc1)ccc1OCC(F)=CCN)=C LPXWSQAEVYFMLL-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 239000004709 Chlorinated polyethylene Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FEAZLBJXMPKFRY-SQQVDAMQSA-N Cl.FC(\C=C\COC1=C(C=C(C=C1)S(=O)(=O)C)Cl)N Chemical compound Cl.FC(\C=C\COC1=C(C=C(C=C1)S(=O)(=O)C)Cl)N FEAZLBJXMPKFRY-SQQVDAMQSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008954 Copper amine oxidases Human genes 0.000 description 1
- 108050000918 Copper amine oxidases Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- RMNHXMZTUFHASA-UHFFFAOYSA-N FC(C=CCOC1=CC=C(C=C1)OC(F)(F)F)N Chemical compound FC(C=CCOC1=CC=C(C=C1)OC(F)(F)F)N RMNHXMZTUFHASA-UHFFFAOYSA-N 0.000 description 1
- QOHQXUNTRPFONC-UHFFFAOYSA-N FC(C=CCOC1=CC=C(C=C1)SC)N Chemical compound FC(C=CCOC1=CC=C(C=C1)SC)N QOHQXUNTRPFONC-UHFFFAOYSA-N 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000056764 GABAA-rho receptor Human genes 0.000 description 1
- 108700010345 GABAA-rho receptor Proteins 0.000 description 1
- 238000005642 Gabriel synthesis reaction Methods 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000195947 Lycopodium Species 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- FHQDWPCFSJMNCT-UHFFFAOYSA-N N(tele)-methylhistamine Chemical compound CN1C=NC(CCN)=C1 FHQDWPCFSJMNCT-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LPDHGKJDGOEWMJ-YCRREMRBSA-N NC/C=C(\COc(cc1)cc(F)c1C#N)/F Chemical compound NC/C=C(\COc(cc1)cc(F)c1C#N)/F LPDHGKJDGOEWMJ-YCRREMRBSA-N 0.000 description 1
- IPZWLNDXOSGASI-GXDHUFHOSA-N NC/C=C(\COc(cc1)ccc1C(Nc1ccccc1)=O)/F Chemical compound NC/C=C(\COc(cc1)ccc1C(Nc1ccccc1)=O)/F IPZWLNDXOSGASI-GXDHUFHOSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100037209 Peroxisomal N(1)-acetyl-spermine/spermidine oxidase Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 101000694612 Rattus norvegicus Membrane primary amine oxidase Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- VHXJIDKXUJAZDV-UHFFFAOYSA-N [4-[4-(cyclohexylcarbamoyl)phenoxy]-3-fluoro-2-methylbut-2-enyl]carbamic acid Chemical compound C1=CC(OCC(F)=C(CNC(O)=O)C)=CC=C1C(=O)NC1CCCCC1 VHXJIDKXUJAZDV-UHFFFAOYSA-N 0.000 description 1
- BTPMBRBDYXJXGA-UHFFFAOYSA-N [4-[4-(cyclohexylcarbamoyl)phenoxy]-3-fluorobut-2-enyl]carbamic acid Chemical compound C1=CC(OCC(F)=CCNC(=O)O)=CC=C1C(=O)NC1CCCCC1 BTPMBRBDYXJXGA-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940106274 anipryl Drugs 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000018093 autoimmune cholangitis Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- CMUHRHATUSDYTQ-UHFFFAOYSA-N chembl1348962 Chemical compound C1=CC(OC)=CC=C1C1=CSC(C=2C=CC(O)=CC=2)=N1 CMUHRHATUSDYTQ-UHFFFAOYSA-N 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001913 cyanates Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940084238 eldepryl Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 229940071670 emsam Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229920005558 epichlorohydrin rubber Polymers 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FVPISMANESAJQZ-UHFFFAOYSA-N ethyl 2-diethoxyphosphoryl-2-fluoroacetate Chemical compound CCOC(=O)C(F)P(=O)(OCC)OCC FVPISMANESAJQZ-UHFFFAOYSA-N 0.000 description 1
- GNJNXPKOEFOWLW-UHFFFAOYSA-N ethyl 2-fluoro-4-[(2-methylpropan-2-yl)oxycarbonylamino]but-2-enoate Chemical compound CCOC(=O)C(F)=CCNC(=O)OC(C)(C)C GNJNXPKOEFOWLW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000007946 hypodermic tablet Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- IVLLBHNEHSLWSZ-UHFFFAOYSA-N n,n-diethyl-4-hydroxybenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(O)C=C1 IVLLBHNEHSLWSZ-UHFFFAOYSA-N 0.000 description 1
- SJYOZHMEVKVOEI-UHFFFAOYSA-N n-(1-adamantyl)-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NC1(C2)CC(C3)CC2CC3C1 SJYOZHMEVKVOEI-UHFFFAOYSA-N 0.000 description 1
- GASKRLASMRUTEM-AAGWESIMSA-N n-[4-[(e)-4-amino-2-fluorobut-2-enoxy]phenyl]acetamide;hydrochloride Chemical compound Cl.CC(=O)NC1=CC=C(OC\C(F)=C/CN)C=C1 GASKRLASMRUTEM-AAGWESIMSA-N 0.000 description 1
- MEDYNGXKKXEBEX-UHFFFAOYSA-N n-benzyl-4-hydroxy-n-methylbenzamide Chemical compound C=1C=C(O)C=CC=1C(=O)N(C)CC1=CC=CC=C1 MEDYNGXKKXEBEX-UHFFFAOYSA-N 0.000 description 1
- FVQDRWUYZFPHLU-UHFFFAOYSA-N n-benzyl-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NCC1=CC=CC=C1 FVQDRWUYZFPHLU-UHFFFAOYSA-N 0.000 description 1
- ZMUOGAYPJMEEQO-UHFFFAOYSA-N n-cyclohexyl-3-fluoro-4-hydroxybenzamide Chemical compound C1=C(F)C(O)=CC=C1C(=O)NC1CCCCC1 ZMUOGAYPJMEEQO-UHFFFAOYSA-N 0.000 description 1
- RIJRDUJYTCDLJV-UHFFFAOYSA-N n-cyclohexyl-4-hydroxybenzenesulfonamide Chemical compound C1=CC(O)=CC=C1S(=O)(=O)NC1CCCCC1 RIJRDUJYTCDLJV-UHFFFAOYSA-N 0.000 description 1
- BVWFBIGOEVEUIM-UHFFFAOYSA-N n-cyclopentyl-4-hydroxybenzamide Chemical compound C1=CC(O)=CC=C1C(=O)NC1CCCC1 BVWFBIGOEVEUIM-UHFFFAOYSA-N 0.000 description 1
- QXUKSWCXRDEVOM-UHFFFAOYSA-N n-tert-butyl-4-hydroxybenzamide Chemical compound CC(C)(C)NC(=O)C1=CC=C(O)C=C1 QXUKSWCXRDEVOM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 125000004316 oxathiadiazolyl group Chemical group O1SNN=C1* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010089000 polyamine oxidase Proteins 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical class NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- CHLCPTJLUJHDBO-UHFFFAOYSA-M sodium;benzenesulfinate Chemical compound [Na+].[O-]S(=O)C1=CC=CC=C1 CHLCPTJLUJHDBO-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000035923 taste sensation Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- BHTQVBHJYOZPCH-BQYQJAHWSA-N tert-butyl n-[(e)-3-fluoro-4-hydroxy-2-methylbut-2-enyl]carbamate Chemical compound OCC(/F)=C(/C)CNC(=O)OC(C)(C)C BHTQVBHJYOZPCH-BQYQJAHWSA-N 0.000 description 1
- JZRUPKCLCRBYRZ-CAPFRKAQSA-N tert-butyl n-[(e)-4-[4-(cyclohexylcarbamoyl)phenoxy]-3-fluoro-2-methylbut-2-enyl]carbamate Chemical compound C1=CC(OCC(/F)=C(CNC(=O)OC(C)(C)C)/C)=CC=C1C(=O)NC1CCCCC1 JZRUPKCLCRBYRZ-CAPFRKAQSA-N 0.000 description 1
- UFCMSOMWZZAYIK-GHRIWEEISA-N tert-butyl n-[(e)-4-[4-(cyclohexylcarbamoyl)phenoxy]-3-fluorobut-2-enyl]carbamate Chemical compound C1=CC(OCC(\F)=C/CNC(=O)OC(C)(C)C)=CC=C1C(=O)NC1CCCCC1 UFCMSOMWZZAYIK-GHRIWEEISA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- ZUHZGEOKBKGPSW-UHFFFAOYSA-N tetraglyme Chemical compound COCCOCCOCCOCCOC ZUHZGEOKBKGPSW-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- YFNKIDBQEZZDLK-UHFFFAOYSA-N triglyme Chemical compound COCCOCCOCCOC YFNKIDBQEZZDLK-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920011532 unplasticized polyvinyl chloride Polymers 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/46—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/27—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- the present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes.
- Invention compounds are useful for treatment of a variety of indications, e.g., the symptoms of inflammation in human subjects as well as in pets and livestock, the treatment of psychological diseases, neurodegenerative disorders, and the like.
- the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses therefor.
- SSAO Semicarbazide-sensitive amine oxidase
- VAP-I vascular adhesion protein-1
- SSAO/VAP-1 is used to describe this protein.
- the role of this protein in inflammatory diseases has been reviewed (see, for example, Smith DJ. and Vaino P.J., Targeting Vascular Adhesion Protein-1 to Treat Autoimmune and Inflammatory Diseases. Ann. N. Y. Acad. Sci. 2007, VoI 1110, pages 382-388; and McDonald LA. et al., Semicarbazide Sensitive Amine Oxidase and Vascular Adhesion Protein-1 : One Protein Being Validated as a Therapeutic Target for Inflammatory Diseases. Annual Reports in Medicinal Chemistry, 2008, VoI 43).
- amine oxidases In most organisms, including humans, two families of mammalian amine oxidases metabolize various mono-, di-, and polyamines produced endogenously or absorbed from exogenous sources. These include the monoamine oxidases (MAO-A and MAO-B) which are present in the mitochondria of most cell types and use covalently bound flavin adenine dinucleotide (FAD) as the cofactor.
- FAD flavin adenine dinucleotide
- Polyamine oxidase is another FAD-dependent amine oxidase which oxidatively deaminates spermine and spermidine.
- SSAO/VAP-1 belongs to the second family which is dependent on copper and uses other co-factors apart from FAD, such as an oxidized tyrosine residue (abbreviated as TPQ).
- TPQ oxidized tyrosine residue
- MAO and SSAO/VAP-1 oxidatively deaminate some common substrates which includes the monoamines such dopamine, tyramine and benzylamine.
- Some of these enzymes were originally defined by the ability of certain compounds to inhibit the enzymatic activity thereof.
- MAO-A is selectively inhibited by clorgyline
- MAO-B by L-deprenyl
- neither clorgyline nor L-deprenyl can inhibit the amine oxidase activity of SSAO/VAP-1.
- S S AO /V AP- 1 can be inhibited by semicarbazide, hence the name semicarbazide sensitive amine oxidase.
- SSAO/VAP-1 is an ectoenzyme containing a very short cytoplasmic tail, a single transmembrane domain, and a large, highly glycosylated extracellular domain which contains the active center for the amine oxidase activity.
- SSAO/VAP-1 is also present in a soluble form circulating in the plasma of some animals. It has been shown that this form is a cleaved product of membrane-bound SSAO/VAP-1. It is currently unclear if there are distinct functions for the membrane and soluble form of SSAO/VAP-1.
- SSAO/VAP-1 appears to have two physiological functions: the first is the amine oxidase activity mentioned above and the second is cell adhesion activity. Both activities are associated with inflammatory processes. SSAO/VAP-1 was shown to play an important role in extravasation of inflammatory cells from the circulation to sites of inflammation (Salmi M. and Jalkanen S., VAP-I: an adhesin and an enzyme. Trends Immunol 2001, 22, 211-216).
- VAP-I antibodies have been demonstrated to attenuate inflammatory processes by blocking the adhesion site of the SSAO/VAP-1 protein, and, together with a substantial body of evidence of in vitro and in vivo knockouts, it is now clear that SSAO/VAP-1 is an important cellular mediator of inflammation.
- Transgenic mice lacking SSAO/VAP-1 show reduced adhesion of leukocytes to endothelial cells, reduced lymphocyte homing to the lymph nodes and a concomitant attenuated inflammatory response in a peritonitis model. These animals were otherwise healthy, grew normally, were fertile, and examination of various organs and tissues showed the normal phenotype.
- Inflammation is the first response of the immune system to infection or irritation.
- the migration of leukocytes from the circulation into tissues is essential for this process.
- Inappropriate inflammatory responses can result in local inflammation of otherwise healthy tissue which can lead to disorders such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and respiratory diseases.
- Leukocytes first adhere to the endothelium via binding to adhesion molecules before they can start the process of passing through the walls of the blood vessels.
- Membrane bound SSAO/VAP-1 is abundantly expressed in vascular endothelial cells such as high venule endothelial cells (HVE) of lymphatic organs and is also expressed in hepatic sinusoidal endothelial cells (HSEC), smooth muscle cells and adipocytes.
- HVE high venule endothelial cells
- HSEC hepatic sinusoidal endothelial cells
- the expression of SSAO/VAP-1 on the cell surface of endothelial cells is tightly regulated and is increased during inflammation, hi the presence of an SSAO/VAP-1 substrate (benzylamine), NFKB was activated in HSECs together with up regulation of other adhesion molecules, E-selectin and chemokine CXCL8 (IL-8) in vitro.
- SSAO/VAP-1 is also highly expressed in adipocytes where it plays a role in glucose transport independent of the presence of insulin. It has been observed that levels of plasma SSAO/VAP-1 are increased in patients suffering from diabetes. Elevated levels of plasma SSAO/VAP-1 have been found in patients suffering from other illnesses, such as congestive heart failure and liver cirrhosis. It is believed that SSAO/VAP-1 is associated with most, if not all, inflammatory diseases whether the inflammation is in response to an immune response or subsequent to other events such as occlusion and reperfusion of blood vessels.
- VAP-I vascular adhesion protein- 1
- EIU endotoxin-induced uveitis
- SSAO/VAP-1 In a mouse overexpressing human SSAO/VAP-1, the SSAO inhibitor Mofegiline significantly attentuates the LPS-induced increase in TNF-a. This inhibitor also significantly reduces BAL cell counts. These results demonstrate that SSAO/VAP-1 is involved in LPS-induced pulmonary inflammation (see, for example, P. Yu et al American Journal of Pathology, 168, 718-726 (2006)). Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious inflammatory disorders of the lung.
- ALI acute lung injury
- ARDS acute respiratory distress syndrome
- SSAO/VAP-1 is upregulated in the liver and serum of patients with inflammatory liver disease; inhibition of SSAO/VAP-1 activity decreases migration of normal lymphocytes across hepatic sinusoidal endothelial cells and has significant effects on the migration of peripheral blood lymphocytes. It has been suggested that the restricted expression of SSAO/VAP-1 and increased production of secreted SSAO/VAP-1 in inflammatory liver disease indicates utility of this protein as a therapeutic target for diseases associated with liver inflammation (see, for example, P. Lalor et al., Ann. N. Y. Acad. Sci. 1110: 485 ⁇ 96 (2007)).
- Monoamine oxidase inhibitors have been used as therapeutic agents for many years (see Tipton, K.F. et al., Monoamine Oxidase and Disease, Academic Press, 1984).
- Monoamine oxidase-B (MAO-B) is an enzyme present on outer mitochondrial membranes, hi man MAO-B oxidatively deaminates dopamine, N- methylhistamine and some trace amines.
- Monoamine oxidase inhibitors have been known for many years and some are clinically prescribed medications for the treatment of Parkinson's disease and more recently for the treatment of CNS disorders such as bipolar depression and attention deficit hyperactivity disorder (ADHD), where dopamine is likely to play an important role in the pathophysiology.
- ADHD attention deficit hyperactivity disorder
- the most well known MAO-B inhibitor is Selegiline (L-deprenyl, Eldepryl® or Anipryl® for veterinary use) which is used to treat Parkinson's disease and senile dementia.
- Selegiline L-deprenyl, Eldepryl® or Anipryl® for veterinary use
- a transdermal patch formulation of Selegiline has been shown to be effective treatment for major depression (Bodkin, J.A. and Amsterdam, J.D., Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients. Am J Psychiatry 2002; 159:1869-1875), and is currently being evaluated in ADHD patients. The drug is also being evaluated to help people stop smoking tobacco and marijuana.
- Inflammation is believed to be an important feature of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and multiple sclerosis, and similarly is a feature of the pathophysiology that occurs after a cerebral occlusion/reperfusion event (Aktas, O. et al., Neuronal damage in brain inflammation. Arch Neurol 2007, 64:185-9).
- Aktas, O. et al. Neuronal damage in brain inflammation. Arch Neurol 2007, 64:185-9.
- Excessive activity of MAO-B and SSAO/VAP-1 has been independently implicated in these processes (Xu, H-L. et al., Vascular Adhesion Protein- 1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia.
- Some known MAO inhibitors also inhibit SSAO/VAP-1 (e.g., the MAO-B inhibitor Mofegiline illustrated below).
- Mofegiline has been reported to inhibit experimental autoimmune encephalomyelitis (US 2006/0025438 Al). This inhibitor is a member of the haloallylamine family of MAO inhibitors; the halogen in Mofegiline is fluorine. Fluorallylamine inhibitors are described in Bey P., US Patent No. 4,454,158 (Allyl amine MAO inhibitors). There have been reports of a chloroallylamine, MDL72274 (illustrated below), selectively inhibiting rat SSAO/VAP-1 compared to MAO-A and MAO-B.
- Haloallylamine compounds that differ from Mofegiline in core structure have been synthesized and were shown to inhibit the amine oxidase activity from copper-dependent amine oxidases from a number of species (see Kim J. et al., Inactivation of bovine plasma amine oxidase by haloallylamines. Bioorg Med Chem 2006, 14, 1444-1453). These compounds have been included in a patent application (Sayre, L. WO 2007/005737).
- the present invention provides substituted haloallylamine compounds that inhibit SSAO/VAP-1.
- modification of 3-substituted-3- haloallylamine structures described in the prior art has led to the discovery of novel compounds that are potent inhibitors of the human SSAO/VAP-1 enzyme.
- certain of these novel compounds are also inhibitors of MAO-B.
- Invention compounds are useful for a variety of applications, e.g., for the treatment of the symptoms of inflammation in human subjects as well as in pets and livestock.
- Human inflammatory diseases include arthritis, Crohn's disease, irritable bowel disease, psoriasis, asthma, chronic pulmonary obstructive disease, bronchiectasis, artherosclerosis, inflammation due to diabetes, and inflammatory cell- mediated tissue destruction following stroke.
- Another aspect of the present invention provides substituted haloallylamine compounds that inhibit SSAO/VAP-1 and MAO- B with similar efficacy.
- SSAO/VAP-1 /MAO-B inhibitors are useful for the treatment of psychological diseases (such as major depression, bipolar depression, and attention deficit hyperactivity disorder), neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), and the like.
- psychological diseases such as major depression, bipolar depression, and attention deficit hyperactivity disorder
- neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease
- the present invention describes the synthesis and use of compounds which inhibit the amine oxidase activity of SSAO/VAP-1, and describes the use of such inhibitors to treat patients suffering inflammatory diseases.
- the present invention describes the synthesis and use of compounds which inhibit both MAO-B and SSAO/VAP-1 at the same time, and describes the use of such inhibitors to treat patients suffering from neurodegenerative processes.
- R 1 is hydrogen or lower alkyl
- R 2 is hydrogen, substituted or unsubstituted lower alkyl, bromine, chlorine or fluorine;
- R 3 and R 4 are independently hydrogen, bromine, chlorine, fluorine, substituted or unsubstituted -alkyl-B-R 5 -R 6 , substituted or unsubstituted -alkenyl-B-R 5 -R 6 , substituted or unsubstituted -alkynyl-B-R 5 -R 6 , substituted or unsubstituted -cycloalkyl-B-R 5 -R 6 , substituted or unsubstituted -cycloalkenyl-B-R 5 -R 6 , or substituted or unsubstituted -heterocyclyl-B-R 5 -R 6 ;
- R 3 and R 4 are bromine, chlorine or fluorine, but both R 3 and R 4 are not bromine, chlorine or fluorine at the same time;
- B is selected from oxygen, sulfur, -S(O) 2 -, -S(O)NH-, -S(O) 2 NH- or -NHC(O)NH-,
- R 5 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted alkenylaryl, substituted or unsubstituted alkenylheteroaryl, substituted or unsubstituted alkynylaryl, or substituted or unsubstituted alkynylheteroaryl; and
- R 6 is hydrogen or a functional group which improves the performance properties of the resulting compounds, e.g., potency, selectivity against MAOB, as well as the solubility and/or drug-like properties of said compound.
- Functional groups which improve the performance properties of the resulting compounds, e.g., potency, selectivity against MAOB, as well as the solubility and/or drug-like properties of invention compounds include radicals bearing such functionalities as morpholines, piperidines, sulfones, sulfonamides, carboxamides, and the like.
- R 6 include:
- each of R 7 and R 8 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, or substituted or unsubstituted alkylheteroaryl; or R 7 and R 8 may cooperate to form a substituted or unsubstituted cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring system;
- R 9 is hydrogen, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido;
- each of R 10 and R 11 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
- R 12 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, alkylheteroaryl, substituted or unsubstituted alkylheteroaryl, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido.
- R 6 Presently preferred examples of R 6 include:
- R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined above.
- “Lower alkyl” alone or in combination means an alkane-derived radical containing from 1 to 6 carbon atoms (unless specifically defined) that includes a straight chain alkyl or branched alkyl.
- the straight chain or branched alkyl group is attached at any available point to produce a stable compound.
- a lower alkyl is a straight or branched alkyl group containing from 1-6, 1-4, or 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, and the like.
- Optionally substituted lower alkyl denotes lower alkyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- fluoro substituted lower alkyl denotes a lower alkyl group substituted with one or more fluoro atoms, such as perfluoroalkyl, where preferably the lower alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms.
- substitutions are attached at any available atom to produce a stable compound
- substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any -O-, -S-, or -N- of the moiety (except where -N- is a heteroaryl ring atom) excludes substituents that would result in any -O-, -S-, or -N- of the substituent (except where -N- is a heteroaryl ring atom) being bound to the alkyl carbon bound to any -O-, -S-, or -N- of the moiety.
- substituted refers to an organic group as defined herein (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
- Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
- a substituted group will be substituted with one or more substituents, unless otherwise specified.
- a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents.
- substituent groups include halogens (i.e., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, alkynoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxyls; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sufides; sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; imines; nitriles (i.e.
- Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and fused ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined herein.
- alkyl refers to hydrocarbyl chains comprising from 1 to 20 carbon atoms.
- alkyl includes straight chain alkyl groups, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like.
- the phrase also includes branched chain isomers of straight chain alkyl groups, including but not limited to, the following which are provided by way of example: -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH 2 CH 3 ) 2 , -CH 2 C(CH 3 ) 3 , -CH 2 C(CH 2 CH 3 ) 3 , -CH(CH 3 )CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH 2 CH(CH 3 ) 2 , -CH 2 CH(CH 3 )(CH 2
- alkyl groups include primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups.
- Preferred alkyl groups include alkyl groups having from 1 to 16 carbon atoms, or from 1 to 3 carbon atoms, such as methyl, ethyl, propyl, and -CH(CH 3 ) 2 .
- alkenyl includes straight chain alkenyl groups, as well as branched chain isomers of straight chain alkenyl groups. Preferably, alkenyl groups comprise from 1 to 8 double bond(s).
- substituted alkenyl refers to an alkenyl group that is substituted according to the definition provided above.
- alkynyl refers to hydrocarbyl chains comprising from 2 to 20 carbon atoms and comprising at least one carbon-carbon triple bond (— C ⁇ C-).
- alkynyl includes straight chain alkynyl groups, as well as branched chain isomers of straight chain alkynyl groups. Preferably, alkynyl groups comprise from 1 to 8 triple bond(s).
- substituted alkynyl refers to an alkynyl group that is substituted according to the definition provided above.
- Aryl alone or in combination refers to a monocyclic or bicyclic ring system containing aromatic hydrocarbons such as phenyl or naphthyl, which may be optionally fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members.
- a "substituted aryl” is an aryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Heteroaryl alone or in combination refers to a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, or a tricyclic aromatic group having 13-15 atoms, wherein heteroaryl contains one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group consisting of O, S, and N. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen.
- heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, benzothiazole, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, and indolyl.
- Nonrogen containing heteroaryl refers to heteroaryl wherein any heteroatoms are N.
- a “substituted heteroaryl” is a heteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkylaryl alone or in combination refers to an alkyl moiety as defined herein, bearing an aryl substituent (as defined herein) appended thereto, and a “substituted alkylaryl” is an alkylaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkylheteroaryl alone or in combination refers to an alkyl moiety as defined herein, bearing a heteroaryl substituent (as defined herein) appended thereto, and a “substituted alkylheteroaryl” is an alkylheteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- alkenylaryl alone or in combination refers to an alkenyl moiety as defined herein, bearing an aryl substituent (as defined herein) appended thereto, and a “substituted alkenylaryl” is an alkenylaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- alkenyheteroaryl alone or in combination refers to an alkenyl moiety as defined herein, bearing a heteroaryl substituent (as defined herein) appended thereto, and a "substituted alkenylheteroaryl” is an alkenylheteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkynylaryl alone or in combination refers to an alkynyl moiety as defined herein, bearing an aryl substituent (as defined herein) appended thereto, and a “substituted alkynylaryl” is an alkynylaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkynylheteroaryl alone or in combination refers to an alkynyl moiety as defined herein, bearing a heteroaryl substituent (as defined herein) appended thereto, and "substituted alkynylheteroaryl” is an alkynylheteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Cycloalkyl refers to saturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and the like.
- a "substituted cycloalkyl” is a cycloalkyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Examples of cycloalkenyl groups include cyclopropenyl, cyclopentenyl, cyclohexenyl, adamantenyl, and the like.
- a "substituted cycloalkenyl” is a cycloalkenyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Heterocyclyl refers to saturated, or unsaturated, but non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, ring members per ring, wherein one or more of the ring members, preferably 1-4, more preferably 1-3, even more preferably 1-2, are heteroatoms independently selected from the group consisting of O, S, and N.
- heterocyclyl When the ring system is saturated, “heterocyclyl” may also be referred to as “cycloheteroalkyl”, and when the ring system is unsaturated, “heterocyclyl” may also be referred to as “cycloheteroalkenyl” or “cycloheteroalkadienyl”, depending on the presence of one or more sites of unsaturation in the ring.
- a "substituted heterocyclyl” is a heterocyclyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkylheterocyclyl refers to an alkyl moiety as defined herein, bearing a heterocyclyl substituent (as defined herein) appended thereto, and a"substituted alkylheterocyclyl” is an alkylheterocyclyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- alkenylheterocyclyl refers to an alkenyl moiety as defined herein, bearing a heterocyclyl substituent (as defined herein) appended thereto, and a"substituted alkenylheterocyclyl” is an alkenylheterocyclyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- Alkynylheterocyclyl refers to an alkynyl moiety as defined herein, bearing a heterocyclyl substituent (as defined herein) appended thereto, and a"substituted alkynylheterocyclyl” is an alkynylheterocyclyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound.
- R 1 is hydrogen
- R 2 is hydrogen, substituted or unsubstituted lower alkyl, bromine, chlorine or fluorine;
- R 3 is bromine, chlorine or fluorine
- R 4 is substituted or unsubstituted -alkyl-B-R 5 -R 6 , substituted or unsubstituted -alkenyl-B-R 5 -R 6 , substituted or unsubstituted -alkynyl-B-R 5 -R 6 , substituted or unsubstituted -cycloalkyl-B-R 5 -R 6 , substituted or unsubstituted -cycloalkenyl-B-R 5 -R 6 , or substituted or unsubstituted -heterocyclyl-B-R 5 -R 6 ;
- B is oxygen, sulfur, -S(O 2 )-, -S(O)NH-, -S(O 2 )NH- or -NHC(O)NH-;
- R 5 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted alkenylaryl, substituted or unsubstituted alkenylheteroaryl, substituted or unsubstituted alkynylaryl, or substituted or unsubstituted alkynyheteroaryl; and
- R 6 is hydrogen or a functional group which improves the performance properties of the resulting compounds, e.g., potency, selectivity against MAOB, as well as the solubility and/or drug-like properties of said compound.
- Functional groups which improve the performance properties of the resulting compounds, e.g., potency, selectivity against MAOB, as well as the solubility and/or drug-like properties of compounds of Formula I include radicals bearing such functionalities as morpholines, piperidines, sulfones, sulfonamides, carboxamides, and the like. Examples of R 6 include:
- each of R 7 and R 8 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, or substituted or unsubstituted alkylheteroaryl; or
- R 7 and R 8 may cooperate to form a substituted or unsubstituted cycloalkyl, cycloalkenyl, or heterocyclyl ring system;
- R 9 is hydrogen, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido;
- each of R 10 and R 11 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or substituted or unsubstituted alkynyl;
- R 12 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido.
- R 6 Presently preferred examples of R 6 include:
- R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are as defined above.
- presently preferred compounds include compounds of Formula I wherein R 3 is fluorine and B is oxygen.
- presently preferred compounds include compounds of Formula I wherein R 3 is chlorine and B is oxygen.
- presently preferred compounds include compounds of Formula I wherein R 4 is methylene; R 5 is substituted aryl; and R 6 is selected from the group consisting of:
- each of R 7 and R 8 are independently hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, or substituted or unsubstituted alkylheteroaryl; or
- R 7 and R 8 may cooperate to form a substituted or unsubstituted cycloalkyl, cycloalkenyl, or heterocyclyl ring system;
- R 9 is hydrogen, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido; each of R 10 and R 11 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, or or unsubstituted alkynyl; and R 12 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, amido, carboximido, lower alkylamido, cycloalkylamido, lower alkylcarboximido, or cycloalkylcarboximido.
- presently preferred compounds include compounds of Formula I wherein R 4 is methylene; R 5 is substituted aryl or benzothiazole; and the remaining R groups are as defined above.
- compounds include the above-described compounds of Formula I wherein R 3 is fluorine and B is oxygen.
- compounds include the above-described compounds of Formula I wherein R 3 is chlorine and B is oxygen.
- compounds described by Formula I may be administered in a prodrug form wherein the substituent R 1 can be selected from such functional groups as -C(O)alkyl, -C(O)aryl, -C(O)-arylalkyl, C(O)heteroaryl, -C(O)-heteroarylalkyl.
- prodrug refers to a compound that, upon in vivo administration, is metabolized by one or more steps or processes or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound.
- Prodrugs can be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to a compound described herein.
- prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when administered to a mammalian subject, can be cleaved to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
- prodrugs include, for example, amides, esters, enol ethers, enol esters, acetates, formates, benzoate derivatives, and the like of alcohol and amine functional groups in the compounds of the present invention.
- inventive compounds described by Formula I may be present as E and Z isomers, also known as cis and trans isomers.
- Compounds of the present invention may have asymmetric centers and may occur, except when specifically noted, as mixtures of stereoisomers or as individual diastereomers, or enantiomers, with all isomeric forms being included in the present invention.
- Compounds of the present invention embrace all conformational isomers.
- Compounds of the present invention may also exist in one or more tautomeric forms, including both single tautomers and mixtures of tautomers.
- inventive compounds described by Formula I may exist as acid addition salts when a basic amino group is present, or as metal salts when an acidic group is present.
- pharmaceutically acceptable salt refers to any salt preparation that is appropriate for use in a pharmaceutical application.
- Pharmaceutically-acceptable salts include amine salts of mineral acids (e.g., hydrochlorides, hydrobromides, sulfates, and the like); and amine salts of organic acids (e.g., formates, acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, maleates, butyrates, valerates, fumarates, alkylsulfonates, arylsulfonates, and the like).
- mineral acids e.g., hydrochlorides, hydrobromides, sulfates, and the like
- organic acids e.g., formates, acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, maleates, butyrates, valerates, fumarates, alkylsulfonates, arylsulfonates
- solvates refers to an aggregation of a molecule and one or more molecules of solvent. Some compounds have a tendency to associate with a fixed molar ratio of solvent molecules in the solid state.
- the solvent molecules may interact with the non-solvent molecule by dipole- dipole interactions, ion-dipole interactions, coordinate bonds, and the like.
- the solvent is water, the solvate is referred to as a hydrate.
- Many organic solvents can also form solvates, including, e.g., ethers such as diethyl ether and tetrahydrofuran, alcohols such as methanol and ethanol, ketones such as acetone, DMF, DMSO and others.
- Solvates may be identified by various methods known in the art. For example, solvates in which the solvent molecules contain hydrogen may be observable by 1 H NMR. Additional methods useful in identifying solvates include thermogravimetric analysis, differential scanning calorimetry, X-ray analysis and elemental analysis. Solvates are readily formed simply by dissolving a compound in a solvent and removing the unassociated solvent by suitable techniques, e.g., evaporation, freeze drying or crystallization techniques. It is therefore well within the skill in the art to produce such solvates. Indeed, it is often the case that careful drying of a compound is necessary to remove the residual solvent that is part of a solvate. Compounds described herein may form solvates and all such solvates are within the scope of the invention.
- Exemplary compounds according to the present invention include compounds having the following structures:
- Exemplary compounds according to the present invention include:
- R 2 , R 3 , B and R 5 are as defined herein; and P 1 is a functional group used to protect a nitrogen functionality.
- Examples of Pi are the tert-butyloxycarbonyl group (BOC) and the phthalimido group.
- a compound represented by Formula III is either directly used in a displacement reaction, such as a Mitsunobu reaction, to yield the compound represented by Formula IV, or is first converted to a bromide, chloride or iodide by procedures well known in the art, then treated with a nucleophilic reagent or organometallic reagent to furnish the compound represented by Formula IV (Method A).
- Mitsunobu reaction conditions are well described in the scientific and patent literature (see, for example, the World Wide Web at en.wikipedia.org/wiki/Mitsunobu_reaction, and Mitsunobu, O., The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28) and proceed by contacting an alcohol with an appropriately substituted phenolic or thiophenolic group, or a substituted phthalimide in the presence of a dialkyl azodicarboxylate and triphenylphosphine in an organic solvent such as tetrahydrofuran (THF) or CH2C12 (CH 2 Cl 2 ).
- THF tetrahydrofuran
- CH2C12 CH2C12
- phenolic compounds described by Formula V such as Formula VI (see Scheme 4), can be converted through an alkylation reaction to compounds described by Formula VII.
- Compounds described by Formula V can be also prepared from compounds of Formula III by procedures in which R 6 R 5 is introduced as a preformed functional entity; see Scheme 6 and Method A; these compounds can be deprotected to the primary amine by the Method B procedures described above to afford the compounds described by Formula 1.
- the preformed functional entities are generally phenol derivatives. Many such phenolic compounds are known in the chemical literature, while others can readily be synthesized by methods well known in the art of synthetic chemistry.
- Reagent 3 can be readily prepared by methods in the art of organic synthesis. See, for example, Scheme 8, wherein the bromide Reagent 1 can be condensed with a mono-protected dihydroxyphenyl compound shown by Reagent 4 according to the Method C described above, followed by deprotection of Intermediate 1 to yield Reagent 3.
- the choice of deprotection methods will depend on the nature of the phenolic protecting group P 2 .
- the synthesis of the starting material described by Formula III can be prepared by a Wittig-Emmons-Horner olefination reaction from the reaction of Reagent 4 with Reagent 5 (see Scheme 9).
- Method E the Wittig- Emmons-Horner Reagent 5 is dissolved in a solvent such as THF, cooled to between - 4O 0 C and 0 0 C, and then treated slowly with a strong base such as n-butyllithium in hexanes.
- a strong base such as n-butyllithium in hexanes.
- the reaction mixture is then quenched with water and the product Intermediate 2 is isolated in the normal way.
- the ester in Intermediate 1 can be reduced to the alcohol in Formula III by Method F, which is exemplary of many methods known in the art of organic synthesis suitable to accomplish such conversion.
- Method F is exemplary of many methods known in the art of organic synthesis suitable to accomplish such conversion.
- diisobutylaluminum hydride in a solvent such as CH 2 Cl 2 can be added to a cold (-4O 0 C to O 0 C) solution of Intermediate 1 , then the reaction mixture is stirred for 1 to 24 hours and the product (described by Formula III) extracted and purified in the normal way.
- the present invention describes methods for the use of compounds described by Formula I to inhibit membrane-bound SSAO/VAP-1 and soluble SSAO/VAP-1.
- the relative inhibitory potencies of the compounds can be determined by the amount needed to inhibit the amine oxidase activity of SSAO/VAP-1 in a variety of ways, e.g., in an in vitro assay with recombinant human protein or with recombinant non-human enzyme, in cellular assays expressing normal rodent enzyme, in cellular assays which have been transfected with human protein, in in vivo tests in rodent and other mammalian species, and the like.
- the relative potencies of examples of compounds described by Formula I are listed in Table 1. Table 1
- compositions comprising a compound having Formula I and at least one pharmaceutically acceptable excipient, carrier or diluent therefor.
- pharmaceutically acceptable carrier refers to any carrier known to those skilled in the art to be suitable for the particular mode of administration, hi addition, the compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
- compositions herein comprise one or more compounds provided herein.
- the compounds are, in one embodiment, formulated into suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation and dry powder inhalers.
- suitable pharmaceutical preparations such as solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations or elixirs, for oral administration or in sterile solutions or suspensions for parenteral administration, as well as transdermal patch preparation and dry powder inhalers.
- the compounds described above are formulated into pharmaceutical compositions using techniques and procedures well known in the art (see, e.g., Ansel Introduction to Pharmaceutical Dosage Forms, Fourth Edition 1985, 126).
- compositions effective concentrations of one or more compounds or pharmaceutically acceptable derivatives thereof is (are) mixed with a suitable pharmaceutical carrier.
- the compounds may be derivatized as the corresponding salts, esters, enol ethers or esters, acetals, ketals, orthoesters, hemiacetals, hemiketals, acids, bases, solvates, hydrates or prodrugs prior to formulation, as described above.
- concentrations of the compounds in the compositions are effective for delivery of an amount, upon administration, that treats, prevents, or ameliorates one or more of the symptoms of diseases or disorders to be treated.
- the compositions are formulated for single dosage administration.
- the weight fraction of compound is dissolved, suspended, dispersed or otherwise mixed in a selected carrier at an effective concentration such that the treated condition is relieved, prevented, or one or more symptoms are ameliorated.
- the active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated.
- the therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems described herein and in PCT publication WO 04/018997, and then extrapolated therefrom for dosages for humans.
- the concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
- a therapeutically effective dosage should produce a serum concentration of active ingredient of from about 0.1 ng/mL to about 50- 100 ⁇ g/mL.
- the pharmaceutical compositions in another embodiment, should provide a dosage of from about 0.001 mg to about 2000 mg of compound per kilogram of body weight per day.
- Pharmaceutical dosage unit forms are prepared to provide from about 0.01 mg, 0.1 mg or 1 mg to about 500 mg, 1000 mg or 2000 mg, and in one embodiment from about 10 mg to about 500 mg of the active ingredient or a combination of essential ingredients per dosage unit form.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
- solubilizing compounds may be used. Such methods are known to those of skill in this art, and include, but are not limited to, using cosolvents, such as dimethylsulfoxide (DMSO), using surfactants, such as TWEEN ® , dissolution in aqueous sodium bicarbonate, formulating the compounds of interest as nanoparticles, and the like. Derivatives of the compounds, such as salts, solvates, prodrugs, and the like, of invention compounds may also be used in formulating effective pharmaceutical compositions.
- cosolvents such as dimethylsulfoxide (DMSO)
- surfactants such as TWEEN ®
- TWEEN ® dissolution in aqueous sodium bicarbonate
- Derivatives of the compounds, such as salts, solvates, prodrugs, and the like, of invention compounds may also be used in formulating effective pharmaceutical compositions.
- the resulting mixture may be a solution, suspension, emulsion or the like.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
- the effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined.
- the pharmaceutical compositions are provided for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions containing suitable quantities of the compounds or pharmaceutically acceptable derivatives thereof.
- the pharmaceutically therapeutically active compounds and derivatives thereof e.g., salts, solvates, or prodrugs thereof, and the like
- Unit-dose forms as used herein refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art.
- Each unit-dose contains a predetermined quantity of the therapeutically active compound sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carrier, vehicle or diluent.
- unit-dose forms include ampoules and syringes and individually packaged tablets or capsules.
- Unit-dose forms may be administered in fractions or multiples thereof.
- a multiple-dose form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dose form.
- Examples of multiple-dose forms include vials, bottles of tablets or capsules or bottles of pints or gallons.
- multiple dose form is a multiple of unit-doses which are not segregated in packaging.
- Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, or otherwise mixing an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
- nontoxic auxiliary substances such as wetting agents, emulsifying agents, solubilizing agents, pH buffering agents and the like, for example, acetate, sodium citrate, cyclodextrine derivatives, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, and other such agents.
- compositions containing active ingredient in the range of 0.005% to 100% (wt%) with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art.
- the contemplated compositions may contain 0.001%-100% (wt%) active ingredient, in one embodiment 0.1-95% (wt%), in another embodiment 75-85% (wt%).
- Oral pharmaceutical dosage forms are either solid, gel or liquid.
- the solid dosage forms are tablets, capsules, granules, and bulk powders.
- Types of oral tablets include compressed, chewable lozenges and tablets which may be enteric-coated, sugar-coated or film-coated.
- Capsules may be hard or soft gelatin capsules, while granules and powders may be provided in non-effervescent or effervescent form with the combination of other ingredients known to those skilled in the art.
- the formulations are solid dosage forms, in one embodiment, capsules or tablets.
- the tablets, pills, capsules, troches and the like can contain one or more of the following ingredients, or compounds of a similar nature: a binder; a lubricant; a diluent; a glidant; a disintegrating agent; a coloring agent; a sweetening agent; a flavoring agent; a wetting agent; an emetic coating; and a film coating.
- binders include microcrystalline cellulose, gum tragacanth, glucose solution, acacia mucilage, gelatin solution, molasses, polvinylpyrrolidine, povidone, crospovidones, sucrose and starch paste.
- Lubricants include talc, starch, magnesium or calcium stearate, lycopodium and stearic acid.
- Diluents include, for example, lactose, sucrose, starch, kaolin, salt, mannitol and dicalcium phosphate.
- Glidants include, but are not limited to, colloidal silicon dioxide.
- Disintegrating agents include crosscarmellose sodium, sodium starch glycolate, alginic acid, corn starch, potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose.
- Coloring agents include, for example, any of the approved certified water soluble FD and C dyes, mixtures thereof; and water insoluble FD and C dyes suspended on alumina hydrate.
- Sweetening agents include sucrose, lactose, mannitol and artificial sweetening agents such as saccharin, and any number of spray dried flavors.
- Flavoring agents include natural flavors extracted from plants such as fruits and synthetic blends of compounds which produce a pleasant sensation, such as, but not limited to peppermint and methyl salicylate.
- Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene laural ether.
- Emetic-coatings include fatty acids, fats, waxes, shellac, ammoniated shellac and cellulose acetate phthalates.
- Film coatings include hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate.
- the compound, or pharmaceutically acceptable derivative thereof could be provided in a composition that protects it from the acidic environment of the stomach.
- the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
- the composition may also be formulated in combination with an antacid or other such ingredient.
- the dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
- the compounds can also be administered as a component of an elixir, suspension, syrup, wafer, sprinkle, chewing gum or the like.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- the active materials can also be mixed with other active materials which do not impair the desired action, or with materials that supplement the desired action, such as antacids, H2 blockers, and diuretics.
- the active ingredient is a compound or pharmaceutically acceptable derivative thereof as described herein. Higher concentrations, up to about 98% by weight of the active ingredient may be included.
- tablets and capsules formulations may be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.
- they may be coated with a conventional enterically digestible coating, such as phenylsalicylate, waxes and cellulose acetate phthalate.
- Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
- Aqueous solutions include, for example, elixirs and syrups.
- Emulsions are either oil- in-water or water-in-oil.
- Elixirs are clear, sweetened, hydroalcoholic preparations.
- Pharmaceutically acceptable carriers used in elixirs include solvents. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may contain a preservative.
- An emulsion is a two-phase system in which one liquid is dispersed in the form of small globules throughout another liquid.
- Pharmaceutically acceptable carriers used in emulsions are non-aqueous liquids, emulsifying agents and preservatives. Suspensions use pharmaceutically acceptable suspending agents and preservatives.
- Pharmaceutically acceptable substances used in non-effervescent granules, to be reconstituted into a liquid oral dosage form include diluents, sweeteners and wetting agents.
- Pharmaceutically acceptable substances used in effervescent granules, to be reconstituted into a liquid oral dosage form include organic acids and a source of carbon dioxide. Coloring and flavoring agents are used in all of the above dosage forms.
- Solvents include glycerin, sorbitol, ethyl alcohol and syrup.
- preservatives include glycerin, methyl and propylparaben, benzoic acid, sodium benzoate and alcohol.
- non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil.
- emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate.
- Suspending agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum and acacia.
- Sweetening agents include sucrose, syrups, glycerin and artificial sweetening agents such as saccharin.
- Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
- Organic acids include citric and tartaric acid.
- Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.
- Coloring agents include any of the approved certified water soluble FD and C dyes, and mixtures thereof.
- Flavoring agents include natural flavors extracted from plants such fruits, and synthetic blends of compounds which produce a pleasant taste sensation.
- the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is in one embodiment encapsulated in a gelatin capsule.
- a gelatin capsule Such solutions, and the preparation and encapsulation thereof, are disclosed in U.S. Patent Nos. 4,328,245; 4,409,239; and 4,410,545.
- the solution e.g., for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be easily measured for administration.
- liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active compound or salt in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g., propylene carbonate) and other such carriers, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
- Other useful formulations include those set forth in U.S. Patent Nos. RE28,819 and 4,358,603.
- such formulations include, but are not limited to, those containing a compound provided herein, a dialkylated mono- or poly-alkylene glycol, including, but not limited to, 1 ,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550- dimethyl ether, polyethylene glycol-750-dimethyl ether wherein 350, 550 and 750 refer to the approximate average molecular weight of the polyethylene glycol, and one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, thiodipropionic acid and its esters, and dithiocarbamates.
- BHT butyl
- compositions include, but are not limited to, aqueous alcoholic solutions including a pharmaceutically acceptable acetal.
- Alcohols used in these formulations are any pharmaceutically acceptable water-miscible solvents having one or more hydroxyl groups, including, but not limited to, propylene glycol and ethanol.
- Acetals include, but are not limited to, di(lower alkyl) acetals of lower alkyl aldehydes such as acetaldehyde diethyl acetal.
- injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- the injectables, solutions and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol.
- compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.
- a compound provided herein is dispersed in a solid inner matrix, e.g., polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethyleneterephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinylacetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinylalcohol and cross-linked partially hydrolyzed polyvinyl acetate, that is surrounded by an outer polymeric membrane, e.g.,
- Parenteral administration of the compositions includes intravenous, subcutaneous and intramuscular administrations. Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions.
- the solutions may be either aqueous or nonaqueous.
- suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
- PBS physiological saline or phosphate buffered saline
- Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances.
- aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection.
- Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil.
- Antimicrobial agents in bacteriostatic or fungistatic concentrations must be added to parenteral preparations packaged in multiple-dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride.
- Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate.
- Antioxidants include sodium bisulfate.
- Local anesthetics include procaine hydrochloride.
- Suspending and dispersing agents include sodium carboxymethylcelluose, hydroxypropyl methylcellulose and polyvinylpyrrolidone.
- Emulsifying agents include Polysorbate 80 (TWEEN ® 80).
- a sequestering or chelating agent of metal ions include EDTA.
- Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
- the concentration of the pharmaceutically active compound is adjusted so that an injection provides an effective amount to produce the desired pharmacological effect.
- the exact dose depends on the age, weight and condition of the patient or animal as is known in the art.
- the unit-dose parenteral preparations are packaged in an ampoule, a vial or a syringe with a needle. All preparations for parenteral administration must be sterile, as is known and practiced in the art.
- intravenous or intraarterial infusion of a sterile aqueous solution containing an active compound is an effective mode of administration.
- Another embodiment is a sterile aqueous or oily solution or suspension containing an active material injected as necessary to produce the desired pharmacological effect.
- Injectables are designed for local and systemic administration.
- a therapeutically effective dosage is formulated to contain a concentration of at least about 0.1% w/w up to about 90% w/w or more, in certain embodiments more than 1% w/w of the active compound to the treated tissue(s).
- the compound may be suspended in micronized or other suitable form or may be derivatized to produce a more soluble active product or to produce a prodrug.
- the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier or vehicle.
- the effective concentration is sufficient for ameliorating the symptoms of the condition and may be empirically determined.
- lyophilized powders which can be reconstituted for administration as solutions, emulsions and other mixtures. They may also be reconstituted and formulated as solids or gels.
- the sterile, lyophilized powder is prepared by dissolving a compound provided herein, or a pharmaceutically acceptable derivative thereof, in a suitable solvent.
- the solvent may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent.
- the solvent may also contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, in one embodiment, about neutral pH.
- the resulting solution will be apportioned into vials for lyophilization.
- Each vial will contain a single dosage or multiple dosages of the compound.
- the lyophilized powder can be stored under appropriate conditions, such as at about 4 °C to room temperature.
- Reconstitution of this lyophilized powder with water for injection provides a formulation for use in parenteral administration.
- the lyophilized powder is added to sterile water or other suitable carrier. The precise amount depends upon the selected compound. Such amount can be empirically determined.
- Topical mixtures are prepared as described for the local and systemic administration.
- the resulting mixture may be a solution, suspension, emulsions or the like and are formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.
- the compounds or pharmaceutically acceptable derivatives thereof may be formulated as aerosols for topical application, such as by inhalation (see, e.g., U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma).
- These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose.
- the particles of the formulation will, in one embodiment, have diameters of less than 50 microns, in one embodiment less than 10 microns.
- the compounds may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application.
- Topical administration is contemplated for transdermal delivery and also for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the active compound alone or in combination with other pharmaceutically acceptable excipients can also be administered.
- Transdermal patches including iotophoretic and electrophoretic devices, are well known to those of skill in the art.
- such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957.
- rectal suppositories are used herein mean solid bodies for insertion into the rectum which melt or soften at body temperature releasing one or more pharmacologically or therapeutically active ingredients.
- Pharmaceutically acceptable substances utilized in rectal suppositories are bases or vehicles and agents to raise the melting point. Examples of bases include cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol) and appropriate mixtures of mono-, di- and triglycerides of fatty acids. Combinations of the various bases may be used.
- spermaceti and wax agents to raise the melting point of suppositories include spermaceti and wax.
- Rectal suppositories may be prepared either by the compressed method or by molding.
- the weight of a rectal suppository in one embodiment, is about 2 to 3 gm.
- Tablets and capsules for rectal administration are manufactured using the same pharmaceutically acceptable substance and by the same methods as for formulations for oral administration.
- the compounds provided herein, or pharmaceutically acceptable derivatives thereof, may also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such targeting methods are well known to those of skill in the art. All such targeting methods are contemplated herein for use in the instant compositions. For non-limiting examples of targeting methods, see, e.g., U.S. Patent Nos.
- liposomal suspensions including tissue-targeted liposomes, such as tumor-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers.
- tissue-targeted liposomes such as tumor-targeted liposomes
- liposome formulations may be prepared according to methods known to those skilled in the art.
- liposome formulations may be prepared as described in U.S. Patent No. 4,522,811. Briefly, liposomes such as multilamellar vesicles (MLVs) may be formed by drying down egg phosphatidyl choline and brain phosphatidyl serine (7:3 molar ratio) on the inside of a flask.
- MLVs multilamellar vesicles
- a solution of a compound provided herein in phosphate buffered saline lacking divalent cations (PBS) is added and the flask shaken until the lipid film is dispersed.
- PBS phosphate buffered saline lacking divalent cations
- the present invention also discloses methods to use the compounds described by Formula I to inhibit SSAO/VAP-1 in patients suffering from an inflammatory disease, and methods to treat inflammatory diseases.
- Human inflammatory diseases include inflammation associated with liver disease, arthritis, Crohn's disease, irritable bowel disease, psoriasis, inflammation associated with respiratory disease (e.g., asthma, bronchitis, chronic pulmonary obstructive disease, bronchiectasis, and the like), artherosclerosis, inflammation due to diabetes, inflammation associated with ocular disease, and tissue destruction by inflammatory cells following stroke.
- the present invention is directed to methods of inhibiting an amine oxidase enzyme in a subject in need thereof, said methods comprising administering to said subject an effective amount of a compound of Formula I to effect a positive therapeutic response.
- the present invention is directed to methods of treating a disease associated with an amine oxidase enzyme, said methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
- the present invention is directed to methods of treating a disease modulated by SSAO/VAP-1 and/or MAO, said methods comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I.
- inflammation embraces a wide variety of indications, including arthritis (including juvenile rheumatoid arthritis), Crohn's disease, ulcerative colitis, inflammatory bowel diseases (e.g., irritable bowel disease), psoriasis, inflammation associated with respiratory disease (e.g., asthma, pulmonary inflammation, chronic pulmonary obstructive disease, bronchitis, bronchiectasis, and the like), skin inflammation, ocular disease (e.g., uveitis), contact dermatitis, liver inflammation, liver autoimmune diseases, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, autoimmune cholangitis, alcoholic liver disease, artherosclerosis, chronic heart failure, congestive heart failure, ischemic diseases, stroke and complications thereof, myocardial infarction and complications thereof, tissue destruction by inflammatory cells
- a particular form of inflammation which is beneficially treated employing invention compounds is ocular disease, especially inflammation of the eye, including uveitis, ulcerative colitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, rhinitis, autoimmune eye inflammation, inflammation driven angiogenesis and lymphogenesis, macular degeneration, and the like.
- the disease is Type I diabetes and complications thereof, Type II diabetes and complications thereof, metabolic syndrome, organ and/or tissue transplant rejection, and the like.
- the disease is a neuroinflammatory disease.
- neuroinflammatory diseases embrace a variety of indications, including stroke, Parkinson's disease, Alzheimer's disease, vascular dimentia, multiple sclerosis, chronic multiple sclerosis, and the like.
- psychiatric disorder embraces a wide variety of indications, including major depression, bipolar depression, attention deficit hyperactivity disorder, and the like.
- the solvent was then removed under reduced pressure and the residue taken up in diethyl ether (20 mL) and water (30 mL), and the pH adjusted to ⁇ pH 1 by addition of 0.1 M HCl (aq.).
- the aqueous layer was extracted with a further portion of diethyl ether (10 mL) before addition of 2 M NaOH solution to bring the pH up to ⁇ pH 12.
- the alkaline layer was extracted with diethyl ether (2 x 20 mL) and the organics combined and washed with brine (10 mL), dried over MgSO 4 , filtered and solvent removed under reduced pressure to afford the amine as a clear oil (0.061 g).
- CD 3 OD CD 3 OD: ⁇ ppm: 3.74 (2 H, d, J 8.2 Hz), 4.56 (2 H, s), 4.86 (2 H, d, obscured by H 2 O peak), 5.56 (1 H, dt, J 18.2, 8.3 Hz), 7.08 (2 H, d, J 8.8 Hz), 7.19-38 (5 H, m), 7.82 (2 H, d, J 8.8 Hz).
- fE)-4-(3-Chloro-4-fluorophenoxy)-3-fluorobut-2-en- 1 -amine hydrochloride was synthesized from fEMert-butyl 3-fluoro-4-hydroxybut-2- enylcarbamate and 3-chloro-4-fluorophenol.
- CEM-(4-Amino-2-fluorobut-2-enyloxy)-2-fluorobenzonitrile hydrochloride was synthesized from ( ⁇ -tert-butyl 3-fiuoro-4-hydroxybut-2- enylcarbamate and 3-fluoro-4-cyanophenol.
- CE y -3-Chloro-4-(2-chloro-4-nitrophenoxy)but-2-en- 1 -amine hydrochloride was synthesized from 3-chloro-4-hydroxybut-2-enylcarbamate and 2- chloro-4-nitrophenol.
- CE>4-(4-tert-Butyl-2-chlorophenoxy)-3-fluorobut-2-en-l -amine hydrochloride was synthesized from (E)-tert-buty ⁇ 3-fluoro-4-hydroxybut-2- enylcarbamate and 4-tert-butyl-2-chlorophenol.
- CE;-4-(4-Amino-2-fluorobut-2-enyloxy)-N,N-dimethylbenzamide hydrochloride was synthesized from (E)-tert-butyl 3-fluoro-4-hydroxybut-2- enylcarbamate and 4-hydroxy-N,N-dimethylbenzamide.
- (E) -4-(4- Amino-2-fluorobut-2-enyloxy)-N,N-diethylbenzenesulfonamide hydrochloride was synthesized from (E)-tert-butyl 3-fluoro-4-hydroxybut-2- enylcarbamate and N,N-diethyl-4-hydroxybenzenesulfonamide.
- CE)-3-Fluoro-4-(4-iodophenoxy)but-2-en-l -amine hydrochloride was synthesized from (E)-tert-huty ⁇ 3-fluoro-4-hydroxybut-2-enylcarbamate and 4- iodophenol.
- CE)-3-Fluoro-4-(4-(pyrrolidin-l -ylsulfonyl)phenoxy)but-2-en-l -amine hydrochloride was synthesized from (E)-tert-butyl 3-fluoro-4-hydroxybut-2- enyl carbamate and 4-(pyrrolidin-l-ylsulfonyl)phenol.
- fEj-4-(4-(Ethylsulfonyl)phenoxy)-3-fluorobut-2-en- 1 -amine hydrochloride was synthesized from (E)-tert-butyl 3-fiuoro-4-hydroxybut-2- enylcarbamate and 4-(ethylsulfonyl)phenol.
- CE)-4-(4-Amino-2-fluorobut-2-enyloxy)-N-tert-butylbenzamide hydrochloride was synthesized from (E)-tert-but ⁇ l 3-fluoro-4-bromobut-2- enylcarbamate and 4-hydroxy-N-tert-butylbenzamide.
- CE y -4-(4-Amino-2-fluorobut-2-enyloxy)-N-phenylbenzamide hydrochloride was synthesized from (E ⁇ -tert-butyl 3-fluoro-4-bromobut-2- enylcarbamate and 4-hydroxy-N-phenylbenzamide.
- CE>7-(4-Amino-2-fluorobut-2-enyloxy)-3-(4-hydroxyphenyl)-4H- chromen-4-one hydrochloride was synthesized from (E)-tert-butyl -3-fluoro-4- bromobut-2-enylcarbamate and 7-hydroxy-3-(4-hydroxyphenyl)-4//-chromen-4-one.
- CE;-3-Fluoro-4-(2-p-tolylbenzo[d]thiazol-6-yloxy)but-2-en-l-amine hydrochloride was synthesized from (E)-tert-butyl 3-fiuoro-4-bromobut-2- enylcarbamate and 2-p-tolylbenzo[d]thiazol-6-ol.
- CE>3-Fluoro-4-(4-(2-(piperidin-l-yl)ethylsulfonyl)phenoxy)but-2-en-l- amine hydrochloride was synthesized from (E)-tert-butyl 3-fluoro-4-bromobut-2- enyl carbamate and 4-(2-(piperidin-l-yl)ethylsulfonyl)phenol.
- CE)-4-(4-Amino-2-fluorobut-2-enyloxy)-N-( 1 -phenyl ethyl)benzene- sulfonamide hydrochloride was synthesized from (E)-tert-buty ⁇ -3-fluoro-4-bromobut- 2-enyl carbamate and 4-hydroxy-N-(l -phenyl ethyl)benzenesulfonamide.
- CE ⁇ -3-Fluoro-4-(phenylsulfonyl)but-2-en- 1 -amine hydrochloride was synthesized from (E)-tert-bxAyl 3-fluoro-4-bromobut-2-enylcarbamate and sodium benzenesulfinate
- CE;-3-Fluoro-4-(2-p-tolylbenzo[d]thiazol-5-yloxy)but-2-en- 1 -amine hydrochloride was synthesized from (2 ⁇ )-tert-butyl 3-fluoro-4-bromobut-2- enylcarbamate and 2-p-tolylbenzo[d]thiazol-5-ol.
- 3T3-L1 Murine fibroblasts were purchased from the American Type Culture Collection (ATCC, Rockville, MD). Dulbecco's Modified Eagle Medium (DMEM) and fetal calf serum (FCS), antibiotics and Amplex® Red were obtained from Invitrogen (Carlsbad, CA). Tissue culture plastics and black clear-bottom 96 well plates were from BD Falcon (Bedford, MA). Bicinchoninic acid (BCA) reagent was from Pierce (Rockford, IL). All other materials were obtained from Sigma (St. Louis, MO).
- DMEM Dulbecco's Modified Eagle Medium
- FCS fetal calf serum
- Amplex® Red obtained from Invitrogen (Carlsbad, CA).
- Tissue culture plastics and black clear-bottom 96 well plates were from BD Falcon (Bedford, MA). Bicinchoninic acid (BCA) reagent was from Pierce (Rockford, IL). All other materials were obtained from Sigma (St. Louis
- 3T3-L1 Fibroblasts were cultured in DMEM supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/L penicillin and 100 ⁇ g/L streptomycin at 37°C in 5% CO2.
- FCS heat-inactivated FCS
- 2 mM L-glutamine 100 U/L penicillin
- 100 ⁇ g/L streptomycin 100 ⁇ g/L streptomycin at 37°C in 5% CO2.
- fibroblasts were cultured in DMEM with FCS for 1 or 2 days postconfluence, after which the cells were cultured for 3 days in DMEM containing 10% FCS, 350 nM insulin, 0.5 mM 3- isobutyl-1-methylxanthine, 250 nM dexamethasone, and 400 nM biotin and for 3 days in DMEM containing 10% FCS and 350 nM insulin.
- adipocytes were maintained in DMEM supplemented with 10% FCS. Adipocytes were used for experiments 8 to 11 days after the onset of differentiation, and the medium was renewed 2 or 3 days prior to each experiment. For culturing in black clear-bottom 96- well plates, cells were seeded at a 1 : 1 cell surface ratio, and differentiation was initiated 4 days postseeding. Cells were used between days 6-12 post-differentiation and between passages 7 and 20. Adipocytes were used as an SSAO source either as adherent cells or as a homogenate.
- HES buffer (20 mM HEPES, 1 mM EDTA, 250 mM sucrose, pH 7.4) and scraped in HES buffer containing 10 ⁇ g/mL leupeptin, 10 ⁇ M pepstatin and 1 mM PMSF.
- Cells were lysed by passage through a 23 G needle followed by passage through di ll G needle. The lysate was spun at 500 g for 5 min and fat was removed. Protein concentration of the supernatant was measured using a BCA assay according to the manufacturer's instructions. The homogenate was stored at -80 0 C until needed.
- adipocyte homogenate 0.5 mg/mL
- adipocytes adipocytes (adhering cells) containing 0.5 mM pargyline, or purified human SSAO was incubated in 0.1 M sodium phosphate buffer pH 7.4 with varying concentrations of test compounds for 30 min at 37 0 C.
- the homogenate was then incubated at 37°C with 60 ⁇ M Amplex® Red, 0.75 LVmL HRP and 40 ⁇ M benzylamine (mouse SSAO) or 300 ⁇ M benzylamine (human SSAO) and the formation of resorufin was measured (excitation range 530-560 nm and emission at 590 nra) every 10 min in either a Tecan Infinite 200 or a BMG plate reader.
- the IC 50 values were estimated using Graphpad Prism software.
- the IC 50 is an estimation of the concentration of the test compound to inhibit the amine oxidase activity of SSAO/VAP-1 by 50%.
- the IC 50 values of certain invention compounds are included in Table 1.
- the murine oxazolone-induced ear edema model is widely used as delayed type hypersensitivity (DTH) model, typically exemplified by allergic contact dermatitis such as eczema.
- DTH delayed type hypersensitivity
- 4 groups of 8 BALB/c mice were sensitized with a topical application of 100 mL of 5% oxazolone in acetone on the shaved ventral abdomen on day -7.
- SSAO/VAP-1 inhibitors were administered by intraperitoneal injection (0 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg) 3 hrs prior to oxazolone challenge.
- Pulmonary neutrophil activation by LPS is used as an in vivo model for allergic asthma, bronchitis and/or chronic obstructive pulmonary disease (COPD).
- LPS initiates neutrophil activation and release of proinflammatory cytokines including TNF- ⁇ and IL-6, followed by neutrophil infiltration into the bronchoalveolae mediated by chemokines such as IL-8 and CXCL5.
- chemokines such as IL-8 and CXCL5.
- Subsequent localized pulmonary injury and inflammation is then further exacerbated by activation of p38 kinase/cJun kinase pathways, metalloproteinases, leukotrienes and iNOS resulting in pulmonary congestion.
- mice Female BALB/c mice weighing 20 to 22 g were fasted overnight prior to use. The test substance and vehicle were administered intraperitoneally (100 mg/kg) to groups of 5 animals at least 3 hours before challenge with -80 ⁇ g/kg of E. CoIi lipopolysaccharide (LPS in sterile saline, 2 ⁇ g in 20 ⁇ L per mouse intratracheally).
- LPS lipopolysaccharide
- mice were anaesthetized by propofol (10 mg/mL, 50 ⁇ L/mouse, i.v.) 24 hours after LPS challenge, 0.25 mL of phosphate buffered saline (PBS) was administered twice through a tracheal cannula after which about 0.3 ml of bronchoalveolar lavage fluid (BALF) was obtained. Total cell number/mL and % neutrophils in BALF are then determined and one-way ANOVA followed by Dunnett's test is used to determine possible significant difference at P ⁇ 0.05.
- PBS phosphate buffered saline
- BALF bronchoalveolar lavage fluid
- Recombinant MAO-B was incubated in 0.1 M sodium phosphate buffer pH 7.4 with varying concentration of test compounds for 30 min at 37°C. The homogenate/protein was then incubated at 37°C with 60 mM Amplex ® Red, 0.75 U/ml HRP and 40 ⁇ M benzylamine (mouse SSAO), 300 ⁇ M benzylamine (human SSAO), 100 ⁇ M tyramine (MAO-A) or 50 ⁇ M benzylamine (MAO-B) and the formation of resorufin was measured (excitation range 530-560 nm and emission at 590 nm) every 5 min in either a Tecan Infinite 200 or a BMG Fluorostar Optima platereader. IC 50 were estimated using Graphpad Prism software. Typical results for exemplary compounds according to the invention are presented in Table 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880125037XA CN101917845A (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
EP08851514.3A EP2222160B1 (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
NZ585528A NZ585528A (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
JP2010534558A JP2011504485A (en) | 2007-11-21 | 2008-11-19 | SSAO / VAP-1 haloallylamine inhibitors and uses thereof |
AU2008327615A AU2008327615B2 (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
CA2706465A CA2706465A1 (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
US12/742,915 US8426587B2 (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
ZA2010/03596A ZA201003596B (en) | 2007-11-21 | 2010-05-20 | Haloallylamine inhibitors of ssao/vap-1 and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98963407P | 2007-11-21 | 2007-11-21 | |
US60/989,634 | 2007-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009066152A2 true WO2009066152A2 (en) | 2009-05-28 |
WO2009066152A3 WO2009066152A3 (en) | 2009-12-30 |
Family
ID=40667907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/003124 WO2009066152A2 (en) | 2007-11-21 | 2008-11-19 | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
Country Status (10)
Country | Link |
---|---|
US (1) | US8426587B2 (en) |
EP (1) | EP2222160B1 (en) |
JP (1) | JP2011504485A (en) |
CN (1) | CN101917845A (en) |
AU (1) | AU2008327615B2 (en) |
CA (1) | CA2706465A1 (en) |
NZ (1) | NZ585528A (en) |
SG (1) | SG186008A1 (en) |
WO (1) | WO2009066152A2 (en) |
ZA (1) | ZA201003596B (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011029996A1 (en) | 2009-09-08 | 2011-03-17 | Biotie Therapies Corp. | Use of vap-1 inhibitors for treating fibrotic conditions |
WO2012120195A1 (en) | 2011-03-08 | 2012-09-13 | Biotie Therapies Corporation | New pyridazinone and pyridone compounds |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013163675A1 (en) | 2012-05-02 | 2013-11-07 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
WO2017136870A1 (en) * | 2016-02-12 | 2017-08-17 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
WO2018073154A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
WO2018149226A1 (en) * | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Amino pyrimidine compounds useful as ssao inhibitors |
WO2018157190A1 (en) * | 2017-03-02 | 2018-09-07 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
US10287270B2 (en) | 2016-08-12 | 2019-05-14 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
WO2019129213A1 (en) * | 2017-12-29 | 2019-07-04 | 广东东阳光药业有限公司 | Amine compound for inhibiting ssao/vap-1 and use thereof |
WO2020006177A1 (en) * | 2018-06-29 | 2020-01-02 | Blade Therapeutics, Inc. | Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof |
WO2020008340A1 (en) * | 2018-07-03 | 2020-01-09 | Yuhan Corporation | Processes for preparing (e)-(2-(chloromethyl)-3-fluoroallyl) carbamate compounds |
WO2020024017A1 (en) | 2018-08-03 | 2020-02-06 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
US10562865B2 (en) | 2018-03-21 | 2020-02-18 | Yuhan Corporation | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same |
EP3626699A4 (en) * | 2017-06-20 | 2020-04-22 | Shandong Danhong Pharmaceutical Co., Ltd. | Ssao inhibitor |
WO2020086747A3 (en) * | 2018-10-24 | 2020-07-23 | Metacrine, Inc. | Ssao inhibitors and uses thereof |
WO2020233583A1 (en) * | 2019-05-20 | 2020-11-26 | 广东东阳光药业有限公司 | Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof |
WO2021012014A1 (en) * | 2019-07-25 | 2021-01-28 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
EP3777846A1 (en) | 2015-12-07 | 2021-02-17 | BenevolentAI Cambridge Limited | Vap-1 inhibitors for treating pain |
US10927106B2 (en) | 2016-10-12 | 2021-02-23 | Pharmasum Therapeutics As | Benzothiazole derivatives as DYRK1 inhibitors |
US10995086B2 (en) | 2018-03-21 | 2021-05-04 | Yuhan Corporation | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same |
US11091479B2 (en) | 2018-12-14 | 2021-08-17 | Yuhan Corporation | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same |
US11168073B2 (en) | 2018-12-14 | 2021-11-09 | Yuhan Corporation | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same |
CN114621189A (en) * | 2020-12-14 | 2022-06-14 | 上海拓界生物医药科技有限公司 | Lactam derivative and application thereof |
US11472769B2 (en) | 2019-10-29 | 2022-10-18 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
RU2801092C2 (en) * | 2018-08-03 | 2023-08-01 | Фармаксис Лтд. | Haloallylamine sulfone derivative as lysiloxidase inhibitors and their use |
US11787791B2 (en) | 2018-09-28 | 2023-10-17 | Acucela Inc. | Inhibitors of VAP-1 |
US11820754B2 (en) | 2020-08-25 | 2023-11-21 | Eli Lilly And Company | Polymorphs of an SSAO inhibitor |
US12037334B2 (en) | 2018-09-28 | 2024-07-16 | Acucela Inc. | Inhibitors of VAP-1 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
CN110366547B (en) * | 2017-03-01 | 2023-02-17 | 勃林格殷格翰国际有限公司 | Transition metal catalyzed photodecarboxylation of alpha-haloacrylic acid derivatives |
WO2018196677A1 (en) * | 2017-04-28 | 2018-11-01 | 四川科伦博泰生物医药股份有限公司 | Fluoroallylamine derivative and use thereof |
CN110914234B (en) * | 2017-08-04 | 2023-06-23 | 广东东阳光药业有限公司 | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine |
CN109810041B (en) * | 2017-11-21 | 2023-08-15 | 药捷安康(南京)科技股份有限公司 | Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof |
CN110938059A (en) * | 2018-09-25 | 2020-03-31 | 上海轶诺药业有限公司 | Preparation and application of aminourea sensitive amine oxidase inhibitor |
CN112876419A (en) * | 2019-11-29 | 2021-06-01 | 四川科伦博泰生物医药股份有限公司 | Allylamine derivatives, process for producing the same and use thereof |
CN114621190B (en) * | 2020-12-14 | 2023-12-05 | 上海拓界生物医药科技有限公司 | Allylamine derivative and application thereof |
Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4364923A (en) | 1972-04-20 | 1982-12-21 | Allen & Hanburs Limited | Chemical compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4454158A (en) | 1981-06-01 | 1984-06-12 | Merrell Toraude Et Compagnie | Allyl amine MAO inhibitors |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5709874A (en) | 1993-04-14 | 1998-01-20 | Emory University | Device for local drug delivery and methods for using the same |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5840674A (en) | 1990-11-01 | 1998-11-24 | Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US5900252A (en) | 1990-04-17 | 1999-05-04 | Eurand International S.P.A. | Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US5972366A (en) | 1994-11-28 | 1999-10-26 | The Unites States Of America As Represented By The Secretary Of The Army | Drug releasing surgical implant or dressing material |
US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6071495A (en) | 1989-12-22 | 2000-06-06 | Imarx Pharmaceutical Corp. | Targeted gas and gaseous precursor-filled liposomes |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6139865A (en) | 1996-10-01 | 2000-10-31 | Eurand America, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
US6253872B1 (en) | 1996-05-29 | 2001-07-03 | Gmundner Fertigteile Gesellschaft M.B.H & Co., Kg | Track soundproofing arrangement |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
US6267983B1 (en) | 1997-10-28 | 2001-07-31 | Bando Chemical Industries, Ltd. | Dermatological patch and process for producing thereof |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US6624202B2 (en) | 2000-07-05 | 2003-09-23 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
WO2004018997A2 (en) | 2002-08-20 | 2004-03-04 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
US20060025438A1 (en) | 2004-02-25 | 2006-02-02 | Salter-Cid Luisa M | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases |
WO2006094201A2 (en) | 2005-03-02 | 2006-09-08 | La Jolla Pharmaceutical Company | Semicarbazide-sensitive amide oxidase inhibitors |
WO2007005737A2 (en) | 2005-07-01 | 2007-01-11 | Case Western Reserve University | Amine oxidase inhibitors |
WO2007120528A2 (en) | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3129826A1 (en) * | 1981-07-29 | 1983-04-28 | Grillo-Werke Ag, 4100 Duisburg | ZINC SALT OF HYDROLIZED TRICARBONIC ACID FROM DIELS-ALDER ADDUCTS OF MALEIC ACID ANHYDRIDE TO UNDECYLENE ACID, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
US4650907A (en) * | 1985-12-05 | 1987-03-17 | Merrell Dow Pharmaceuticals Inc. | Nonaromatic fluoroallylamine MAO inhibitors |
DD246990A1 (en) * | 1986-02-26 | 1987-06-24 | Univ Leipzig | METHOD FOR PRODUCING GAMMA-CHLOROALLYL COMPOUNDS FROM POLYCHLORALKANES |
FI890827A (en) | 1988-02-25 | 1989-08-26 | Merrell Dow Pharma | LYSYLOXIDAS-INHIBITORER. |
AU663582B2 (en) | 1992-03-04 | 1995-10-12 | Akzo N.V. | In vivo binding pair pretargeting |
US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
DE4438017C2 (en) * | 1994-10-25 | 1996-10-31 | Bosch Gmbh Robert | Method and device for the electrical control or regulation of the brake system of a vehicle |
US5565602A (en) * | 1995-03-13 | 1996-10-15 | Phillips Petroleum Company | Production of thiolcarbamates |
JP3333101B2 (en) * | 1996-11-27 | 2002-10-07 | シャープ株式会社 | Manufacturing method of optical coupler |
US5860674A (en) * | 1997-01-31 | 1999-01-19 | Robert Bosch Corporation | AOS fan modulation systems |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6256633B1 (en) * | 1998-06-25 | 2001-07-03 | U.S. Philips Corporation | Context-based and user-profile driven information retrieval |
GB2408071B (en) | 2002-08-17 | 2005-10-19 | Siemens Magnet Technology Ltd | Pressure relief valve for a helium gas compressor |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
EP1633861B1 (en) * | 2003-05-26 | 2009-11-04 | Biotie Therapies Corp. | Crystalline vap-1 and uses thereof |
CN1921841A (en) * | 2004-02-25 | 2007-02-28 | 拉卓拉药物公司 | Amines and amides for the treatment of diseases |
ITMI20041154A1 (en) * | 2004-06-09 | 2004-09-09 | Italiana Sint Spa | SUMMARY PROCEDURE OF TERBINAFINA AND ITS DERIVATIVES |
US20070021365A1 (en) | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
US7540564B2 (en) | 2006-03-30 | 2009-06-02 | Esther Gokhale | Ergonomic systems and devices |
-
2008
- 2008-11-19 NZ NZ585528A patent/NZ585528A/en not_active IP Right Cessation
- 2008-11-19 CA CA2706465A patent/CA2706465A1/en not_active Abandoned
- 2008-11-19 WO PCT/IB2008/003124 patent/WO2009066152A2/en active Application Filing
- 2008-11-19 US US12/742,915 patent/US8426587B2/en not_active Expired - Fee Related
- 2008-11-19 JP JP2010534558A patent/JP2011504485A/en active Pending
- 2008-11-19 AU AU2008327615A patent/AU2008327615B2/en not_active Ceased
- 2008-11-19 CN CN200880125037XA patent/CN101917845A/en active Pending
- 2008-11-19 EP EP08851514.3A patent/EP2222160B1/en not_active Not-in-force
- 2008-11-19 SG SG2012084919A patent/SG186008A1/en unknown
-
2010
- 2010-05-20 ZA ZA2010/03596A patent/ZA201003596B/en unknown
Patent Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
US4364923A (en) | 1972-04-20 | 1982-12-21 | Allen & Hanburs Limited | Chemical compounds |
US4414209A (en) | 1972-04-20 | 1983-11-08 | Allen & Hanburys Limited | Micronized aerosol steroids |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4454158B1 (en) | 1981-06-01 | 1992-12-22 | Merrell Toraude & Co | |
US4454158A (en) | 1981-06-01 | 1984-06-12 | Merrell Toraude Et Compagnie | Allyl amine MAO inhibitors |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US6071495A (en) | 1989-12-22 | 2000-06-06 | Imarx Pharmaceutical Corp. | Targeted gas and gaseous precursor-filled liposomes |
US5900252A (en) | 1990-04-17 | 1999-05-04 | Eurand International S.P.A. | Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon |
US5840674A (en) | 1990-11-01 | 1998-11-24 | Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5709874A (en) | 1993-04-14 | 1998-01-20 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5972366A (en) | 1994-11-28 | 1999-10-26 | The Unites States Of America As Represented By The Secretary Of The Army | Drug releasing surgical implant or dressing material |
US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US6253872B1 (en) | 1996-05-29 | 2001-07-03 | Gmundner Fertigteile Gesellschaft M.B.H & Co., Kg | Track soundproofing arrangement |
US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
US6139865A (en) | 1996-10-01 | 2000-10-31 | Eurand America, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
US6267983B1 (en) | 1997-10-28 | 2001-07-31 | Bando Chemical Industries, Ltd. | Dermatological patch and process for producing thereof |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
US6624202B2 (en) | 2000-07-05 | 2003-09-23 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
WO2004018997A2 (en) | 2002-08-20 | 2004-03-04 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
US20060025438A1 (en) | 2004-02-25 | 2006-02-02 | Salter-Cid Luisa M | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases |
WO2006094201A2 (en) | 2005-03-02 | 2006-09-08 | La Jolla Pharmaceutical Company | Semicarbazide-sensitive amide oxidase inhibitors |
WO2007005737A2 (en) | 2005-07-01 | 2007-01-11 | Case Western Reserve University | Amine oxidase inhibitors |
WO2007120528A2 (en) | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
Non-Patent Citations (27)
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10576148B2 (en) | 2009-09-08 | 2020-03-03 | Biotie Therapies Corp. | Use of VAP-1 inhibitors for treating fibrotic conditions |
JP2013503915A (en) * | 2009-09-08 | 2013-02-04 | バイオティ セラピーズ コーポレイション | Use of VAP-1 inhibitors for the treatment of fibrotic diseases |
WO2011029996A1 (en) | 2009-09-08 | 2011-03-17 | Biotie Therapies Corp. | Use of vap-1 inhibitors for treating fibrotic conditions |
JP2018104445A (en) * | 2009-09-08 | 2018-07-05 | バイオティ セラピーズ コーポレイション | Use of vap-1 inhibitors for treating fibrotic conditions |
US9795671B2 (en) | 2009-09-08 | 2017-10-24 | Biotie Therapies Corp. | Use of VAP-1 inhibitors for treating fibrotic conditions |
JP2016147847A (en) * | 2009-09-08 | 2016-08-18 | バイオティ セラピーズ コーポレイション | Use of vap-1 inhibitors for treating fibrotic diseases |
WO2012120195A1 (en) | 2011-03-08 | 2012-09-13 | Biotie Therapies Corporation | New pyridazinone and pyridone compounds |
EP2567959A1 (en) | 2011-09-12 | 2013-03-13 | Sanofi | 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9302986B2 (en) | 2012-05-02 | 2016-04-05 | Boehringer Ingelheim International Gmbh | Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof |
EP3438087A1 (en) | 2012-05-02 | 2019-02-06 | Boehringer Ingelheim International GmbH | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
AU2013255103B2 (en) * | 2012-05-02 | 2016-09-29 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
AU2013203655B2 (en) * | 2012-05-02 | 2017-02-02 | Boehringer Ingelheim International Gmbh | Haloallylamine inhibitors of SSAO-VAP-1 and uses therefor |
KR102089935B1 (en) * | 2012-05-02 | 2020-03-18 | 베링거 인겔하임 인터내셔날 게엠베하 | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
KR20150014926A (en) * | 2012-05-02 | 2015-02-09 | 파맥시스 엘티디 | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
US9815782B2 (en) | 2012-05-02 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
WO2013163675A1 (en) | 2012-05-02 | 2013-11-07 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
US10160723B2 (en) | 2012-05-02 | 2018-12-25 | Boehringer Ingelheim International Gmbh | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
EP3777846A1 (en) | 2015-12-07 | 2021-02-17 | BenevolentAI Cambridge Limited | Vap-1 inhibitors for treating pain |
EP3414244A4 (en) * | 2016-02-12 | 2019-11-27 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
AU2017217238B2 (en) * | 2016-02-12 | 2021-05-20 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
EA037302B1 (en) * | 2016-02-12 | 2021-03-09 | Фармаксис Лтд. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
US11098045B2 (en) | 2016-02-12 | 2021-08-24 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
EP3414226A4 (en) * | 2016-02-12 | 2019-12-18 | Pharmaxis Ltd. | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
US10717734B2 (en) | 2016-02-12 | 2020-07-21 | Pharmaxis Ltd. | Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof |
US10717733B2 (en) | 2016-02-12 | 2020-07-21 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
WO2017136870A1 (en) * | 2016-02-12 | 2017-08-17 | Pharmaxis Ltd. | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof |
US10287270B2 (en) | 2016-08-12 | 2019-05-14 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
US10464928B2 (en) | 2016-08-12 | 2019-11-05 | Eli Lilly And Company | Amino pyrimidine SSAO inhibitors |
US10793552B2 (en) | 2016-08-12 | 2020-10-06 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
US10927106B2 (en) | 2016-10-12 | 2021-02-23 | Pharmasum Therapeutics As | Benzothiazole derivatives as DYRK1 inhibitors |
WO2018073154A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
WO2018149226A1 (en) * | 2017-02-14 | 2018-08-23 | Eli Lilly And Company | Amino pyrimidine compounds useful as ssao inhibitors |
US10471060B2 (en) | 2017-02-14 | 2019-11-12 | Eli Lilly And Company | Amino pyrimidine compounds useful as SSAO inhibitors |
US10278970B2 (en) | 2017-02-14 | 2019-05-07 | Eli Lilly And Company | Amino pyrimidine compounds useful as SSAO inhibitors |
WO2018157190A1 (en) * | 2017-03-02 | 2018-09-07 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
EP3626699A4 (en) * | 2017-06-20 | 2020-04-22 | Shandong Danhong Pharmaceutical Co., Ltd. | Ssao inhibitor |
US11505532B2 (en) | 2017-06-20 | 2022-11-22 | Shandong Danhong Pharmaceutical Co., Ltd. | SSAO inhibitor |
US11001563B2 (en) | 2017-06-20 | 2021-05-11 | Shandong Danhong Pharmaceutical Co., Ltd. | SSAO inhibitor |
WO2019129213A1 (en) * | 2017-12-29 | 2019-07-04 | 广东东阳光药业有限公司 | Amine compound for inhibiting ssao/vap-1 and use thereof |
CN109988109B (en) * | 2017-12-29 | 2020-12-29 | 广东东阳光药业有限公司 | Amine compound for inhibiting SSAO/VAP-1 and application thereof |
CN109988109A (en) * | 2017-12-29 | 2019-07-09 | 广东东阳光药业有限公司 | Inhibit the aminated compounds and application thereof of SSAO/VAP-1 |
US10562865B2 (en) | 2018-03-21 | 2020-02-18 | Yuhan Corporation | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same |
US10899719B2 (en) | 2018-03-21 | 2021-01-26 | Yuhan Corporation | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same |
US11492335B2 (en) | 2018-03-21 | 2022-11-08 | Yuhan Corporation | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same |
US11780830B2 (en) | 2018-03-21 | 2023-10-10 | Yuhan Corporation | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same |
US10995086B2 (en) | 2018-03-21 | 2021-05-04 | Yuhan Corporation | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same |
WO2020006177A1 (en) * | 2018-06-29 | 2020-01-02 | Blade Therapeutics, Inc. | Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof |
WO2020008340A1 (en) * | 2018-07-03 | 2020-01-09 | Yuhan Corporation | Processes for preparing (e)-(2-(chloromethyl)-3-fluoroallyl) carbamate compounds |
US11332436B2 (en) | 2018-07-03 | 2022-05-17 | Yuhan Corporation | Processes for preparing (E)-(2-(chloromethyl)-3-fluoroallyl) carbamate compounds |
WO2020024017A1 (en) | 2018-08-03 | 2020-02-06 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
CN112533897A (en) * | 2018-08-03 | 2021-03-19 | 法玛西斯有限公司 | Haloallylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof |
US20210353571A1 (en) * | 2018-08-03 | 2021-11-18 | Pharmaxis Ltd. | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
RU2801092C2 (en) * | 2018-08-03 | 2023-08-01 | Фармаксис Лтд. | Haloallylamine sulfone derivative as lysiloxidase inhibitors and their use |
CN112533897B (en) * | 2018-08-03 | 2023-07-14 | 法玛西斯有限公司 | Halogenated allylamine sulfone derivative inhibitors of lysyl oxidase and uses thereof |
US11787791B2 (en) | 2018-09-28 | 2023-10-17 | Acucela Inc. | Inhibitors of VAP-1 |
US12037334B2 (en) | 2018-09-28 | 2024-07-16 | Acucela Inc. | Inhibitors of VAP-1 |
WO2020086747A3 (en) * | 2018-10-24 | 2020-07-23 | Metacrine, Inc. | Ssao inhibitors and uses thereof |
CN113226296A (en) * | 2018-10-24 | 2021-08-06 | 梅塔科林公司 | SSAO inhibitors and uses thereof |
US11091479B2 (en) | 2018-12-14 | 2021-08-17 | Yuhan Corporation | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same |
US11713308B2 (en) | 2018-12-14 | 2023-08-01 | Yuhan Corporation | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same |
US11168073B2 (en) | 2018-12-14 | 2021-11-09 | Yuhan Corporation | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same |
US11820769B2 (en) | 2018-12-14 | 2023-11-21 | Yuhan Corporation | Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same |
WO2020233583A1 (en) * | 2019-05-20 | 2020-11-26 | 广东东阳光药业有限公司 | Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof |
WO2021012014A1 (en) * | 2019-07-25 | 2021-01-28 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
US11472769B2 (en) | 2019-10-29 | 2022-10-18 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
US11964942B2 (en) | 2019-10-29 | 2024-04-23 | Eccogene (Shanghai) Co., Ltd. | SSAO inhibitors and use thereof |
US11820754B2 (en) | 2020-08-25 | 2023-11-21 | Eli Lilly And Company | Polymorphs of an SSAO inhibitor |
CN114621189A (en) * | 2020-12-14 | 2022-06-14 | 上海拓界生物医药科技有限公司 | Lactam derivative and application thereof |
CN114621189B (en) * | 2020-12-14 | 2024-01-02 | 上海拓界生物医药科技有限公司 | Lactam derivative and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU2008327615A1 (en) | 2009-05-28 |
US8426587B2 (en) | 2013-04-23 |
CA2706465A1 (en) | 2009-05-28 |
EP2222160A2 (en) | 2010-09-01 |
AU2008327615B2 (en) | 2014-08-21 |
SG186008A1 (en) | 2012-12-28 |
WO2009066152A3 (en) | 2009-12-30 |
EP2222160B1 (en) | 2015-03-18 |
CN101917845A (en) | 2010-12-15 |
US20100298330A1 (en) | 2010-11-25 |
JP2011504485A (en) | 2011-02-10 |
EP2222160A4 (en) | 2011-02-16 |
ZA201003596B (en) | 2011-02-23 |
NZ585528A (en) | 2012-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2222160B1 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
US10160723B2 (en) | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof | |
US20080090827A1 (en) | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | |
US20090264469A1 (en) | Novel dicarboxylic acid derivatives | |
WO1996036595A1 (en) | 3,4-disubstituted-phenylsulphonamides and their therapeutic use | |
JP4806734B2 (en) | Benzimidazole derivatives | |
EP1757607A1 (en) | N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases | |
CS225850B2 (en) | Process for preparing new r,r-n-(2-phenyl-2-hydroxyethyl)-1-methyl-3-phenylpropylamines | |
WO2002006210A1 (en) | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists | |
JP2012506418A (en) | Tetrahydronaphthalene compound | |
US20230257342A1 (en) | Haloallylamine dual amine oxidase inhibitors | |
SK6522003A3 (en) | Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same | |
EP1292572A1 (en) | Propanolaminotetralines, preparation thereof and compositions containing same | |
JP4852230B2 (en) | Propanolaminomethyltetralin, process for producing them and pharmaceutical composition containing them | |
WO2023091565A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof | |
JP2005511687A6 (en) | Propanolaminomethyltetralin, process for producing them and pharmaceutical composition containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880125037.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08851514 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010534558 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008327615 Country of ref document: AU Ref document number: 2706465 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 585528 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008327615 Country of ref document: AU Date of ref document: 20081119 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008851514 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12742915 Country of ref document: US |